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Abstract 
Nanomedicine- where a therapeutic is loaded into nanoparticles to increase therapeutic efficiency 
and improve patient outcomes- has long had the potential to revolutionize medicine. With all of 
their promise, nanoparticle carrier technologies have yet to make a significant clinical impact, 
emphasizing the need for new technologies and approaches. In this dissertation, 
electrohydrodynamic (EHD) co-jetting was used to develop various methods to create novel 
Synthetic Protein Nanoparticles (SPNPs), which were then applied to the delivery of therapeutic 
enzymes, and characterized using a microfluidic technique. It was found that SPNPs can be made 
from various proteins, such as Human Transferrin, Hemoglobin, and others, and that various 
macromers can be selected, such as a stimuli responsive NHS-Ester based macromer that can 
detect oxidative environments and show signs of degradation after being taken up by HeLa cells. 
SPNPs were then loaded with medically relevant enzymes, such as the antioxidant enzyme 
catalase. The enzymes showed high activity retention rates, with catalase SPNPs maintaining up 
to 82% of their original enzymatic activity. Additionally, antibody-targeted catalase SPNPs were 
able to protect REN cells in an inflammatory disease model. Next, an electrokinetic microfluidic 
system was adapted for the characterization of SPNPs based on their protein composition and 
anisotropy. The method was able to differentiate bicompartmental particles made from two 
different proteins from single compartment SPNPs made of an equivalent isotropic mixture of the 
same two proteins, with a significant voltage difference between the two particle types. Finally, 
preliminary work was conducted on using a small targeting molecule, meta-
acetylenbenzylguanidine (MABG), for the treatment of neuroblastoma, and a system for validating 
MABG targeting in SK-N-BE(2) cells (a neuroblastoma cell line) was developed. Work done in 
this dissertation presents the development of multifunctional protein nanocarriers and lays the 
groundwork for the targeted delivery of active therapeutics using these particles.
1 
Chapter 1 
Introduction 
 
Part of the material for this chapter has been adapted with modifications from the following 
publication: 
 
1. N. Habibi*, D. F. Quevedo*, J. V. Gregory*, J. Lahann, “Emerging Methods in 
Therapeutics Using Multifunctional Nanoparticles” WIREs Nanomedicine & 
Nanobiotechnology 2020, 12(4):e1625 
*equal contribution 
 
 Background on Nanotechnology in Medicine and its Shortcomings 
Nanoparticles, synthetic material with at least one dimension in the nanoscale (Figure 1.1), 
have become a thriving area of science along a broad range of disciplines over the last 40 years. 
The conception of the idea of nanotechnology is widely attributed to the prolific Richard Feynman 
in 19591–3 as a way to make smaller machines which could eventually allow the manipulation of 
matter at the atomic level. Nanotechnology has now become a reality, revolutionizing fields as 
2 
varied as electronics,4,5 automobiles,6 space technologies,7–9 architecture,10 and even in the analysis 
and conservation of works of art.11–13 
Figure 1.1 Nanoparticles are materials that have at least one dimension in the nanoscale, a size 
range signified by the red oval. 
In the medical space, nanotechnology promises to leave its small-scale, but largely 
impactful, footprints in various ways. Nanoparticle-based drug delivery has emerged as an 
application of nanotechnology, whose aim is to improve shortcomings in traditional small 
molecule-based therapeutics by loading active therapeutic ingredients in nanoparticles.14,15 The 
goal is to use the nanoparticles to specifically deliver a therapeutic to the diseased site. This 
delivery can be done in a variety of ways: passive accumulation using the theorized but much 
debated Enhanced Permeability and Retention (EPR) effect,16 attaching targeting molecules that 
are specific to biomarkers expressed on target cell surfaces,17,18 incorporating groups, such as 
magnetic nanoparticles, that allow for non-invasive control of particle location,19,20 or even using  
the body’s own delivery network and carriers, the cardiovascular system and blood cells, to carry 
nanoparticles to their desired locations, as is done with hitchhiking nanoparticles.21–24 By having 
nanoparticles specifically target diseased parts of the body, along with other advancements, such 
as high loading ratios of therapeutics18 and stimuli responsive site specific release,25 the field of 
nanomedicine aims to make ineffective therapies viable, reduce side effects of high morbidity 
3 
treatments such as chemo- and radiotherapy, improve the performance of existing therapies, and 
overall improve patient outcomes.26,27 Nanomedical applications in cancer hold particular promise 
and are a highly active area of research.28 
Nanoparticles in medicine have been developed from a wide variety of materials, both 
organic and inorganic, using a large number of techniques. These methods range from liposomal 
forms of drugs, such as Doxil, a PEGylated liposomal formulation of doxorubicin,29 which in 1995 
became the first nanotherapeutic approved by the FDA, to taking inspiration from applications in 
in vitro and in vivo fluorescent imaging,30–33 dual use therapeutic/diagnostic (theragnostic) 
systems,34–37 stimuli responsive materials,26,38–43 and all the way to self-assembling materials made 
from proteins,44 DNA,45 small organic molecules,46 and even inspired by viruses.47 However, the 
promise of nanomedicine, the tremendous advance of the techniques and technologies, and the 
large amount of research time that has been invested, does not seem to reflect the real-world 
outcomes. For example, in the years between 2016-2019, only 3 new nanoformulations were 
approved by the FDA,48 compared to the 153 formulations that were approved overall.49 This 
number is contextually even more depressing in light of the fact that in the 25 years since the 
approval of Doxil, only around 30 nanotherapeutics have been approved, of which only 10 were 
cancer nanomedicines.50 Compared to the approximately 35-40 new formulations (a number which 
includes drugs, biologics, and vaccines) approved per year,51 there is a general disappointment in 
the field about the lack of translation of nanomedicine from the bench to the bedside. This lack of 
translation was highlighted in the seminal work by Wilhelm et al in 2016, whose extensive 
literature review and metanalysis found that only a median of 0.7% of administered nanoparticles 
are delivered to solid tumors.52  
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This disappointment has led to an avalanche of questions about why nanomedicine, and 
cancer nanomedicine in particular, has had limited clinical success.53–58 New research has 
indicated that this may be due, in parts, to the limitations of the principle behind the EPR effect.59 
The EPR effect is a theory established in 1986, when evidence suggested that the vasculature in 
solid tumors is “leaky”, containing large (2000 nm) gaps.60,61 The theory postulates that these gaps 
lead to enhanced permeability of particles to tumors, and low blood flow rates along with 
incomplete lymphatic clearance lead to enhanced retention of particulates once inside the tumor 
(thus, Enhanced Permeability and Retention, or EPR).16 Thus, nanoparticles have been developed 
with the aim for the delivery carriers to be small enough to enter these fenestrations but not so 
small as to be cleared by the other mechanisms in the body.62,63 New research by Sindhwani et al. 
has found, in a variety of tumor models and patient samples, that these fenestrations are actually 
quite rare. Additionally, they found that the main method for tumor uptake of nanoparticles is 
actually through active extravasation, or the uptake of particles by endothelial cells that line blood 
vessels and their subsequent expulsion into solid tumors.59 As this evidence contradicts one of the 
main design principles in nanomedicine, it may explain their disappointing translation to the clinic. 
Perhaps, the reason why nanomedicines have been ineffective is that they have been designed to 
take advantage of a quality of solid tumors that never existed in the first place. 
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Figure 1.2 Examples of the materials commonly used in nanomedicine. 
This new evidence points to a new way forward for nanomedicine. The inherent ability of 
materials currently popular in nanomedicine (polymers, liposomes, inorganics, etc., Figure 1.2) to 
actively extravasate has generally not been studied well, but the lack of translation suggests that 
these materials are not ideal. This leads to the thought: why not explore new materials that are built 
to take advantage of this new discovery, potentially even taking inspiration from nature? A prime 
example of this methodology is Abraxane, one of the few approved nanomedicines, a nanoparticle 
built out of physically linked proteins (Human Serum Albumin to be specific) and loaded with 
paclitaxel.64 Abraxane demonstrates decreased morbidity compared to the free drug formulation 
of paclitaxel, whose organic solvent Cremphor EL causes a variety of side effects.65 Abraxane also 
has shown improvements in patient outcomes, and a popular argument for the improvements in 
patient outcomes is the fact that albumin interacts with the glycoprotein gp60, which induces 
extravasation of the drug-protein complex.66,67 This has led to a recent development in the field of 
nanoparticle-based drug delivery, where synthetic polymers and inorganics are replaced by 
proteins as the primary building blocks of nanoparticles. 
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 Proteins in Medicine and Nanomedicine 
1.2.1 Background on Proteins and their Applications in Medicine 
As a material, proteins show great promise for clinical application due to their variety, 
function, design flexibility through genetic engineering, and potential lack of immunogenicity. 
Proteins are made from chains of amino acids, which can be characterized as having two main 
components: the group that becomes the carbon-amide backbone, and the side group (-R) (Figure 
1.3A). The genetic code of organisms is made up of nucleic acids, every three of which make up 
a codon, and encode for 20 different α-amino acids (identical backbones, different -R groups). This 
genetic code, made up of DNA, is transcribed into RNA, and subsequently “translated” into 
proteins through biochemical processes. RNA is used as a template from which the proteins are 
“printed” by ribosomes. This printing occurs by reacting amines from one amino acid with the 
carboxylic acid of the next amino acid, one at a time, resulting in a process much like adding beads 
to the end of a string (Figure 1.3B).  
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Figure 1.3 Proteins are complex biomolecules. (A) They are made up of amino acids that (B) 
Polymerize into chains, whose intermolecular interactions, and other outside factors, (C) cause 
them to fold into complex 3D structures. Ribbon representation of Human Serum Albumin from 
PDB 1A06.68 
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A variety of mechanisms cause the resulting polypeptide chain to fold into the complex 
three-dimensional shape distinctive of proteins (Figure 1.3C). For example, the hydrophobic or 
hydrophilic nature of each -R group on an amino acid will cause it to prefer the inside of outside 
of the structure when it is in water (hydrophobic groups will “hide” inside the structure, and vice 
versa). Other -R groups will have chemical interactions with each other, such as van der Waals 
interactions, hydrogen bonds, or ionic bonds. Additionally, the different environments within cells 
that that proteins go through as they are being made will chemically modify certain -R groups and 
make them form covalent bonds with each other. For example, cysteines, which contain a thiols (-
SH) in their -R group, can lose their H atoms in reducing environments within the cells, and 
subsequently react with other reduced cysteines to result in disulfide bridges.69,70 
All these interactions that result in three dimensional structures give rise to what is arguably 
the main key concept in biochemistry: structure gives rise to function. Evolutionary processes have 
resulted in a broad range of proteins that can interact with their environments in a variety of ways. 
For example, they can specifically capture small molecules in enzymatic pockets. Once captured, 
the small molecule causes a small change in the local forces in the protein, and the resulting change 
in 3D structure can catalyze reactions of the small molecule, such as hydrolysis reactions to “split” 
the molecule in tow and consume a water molecule in the process (as performed by penicillin 
amylase).71 The opposite is also possible, where a protein captures two molecules, and combines 
the two through a condensation reaction, producing a water molecule in the process (as happens 
with citrate synthase).72 Many other chemical reactions are possible through enzymatic catalysis. 
Proteins are also able to produce physical actuation forces, such as the interactions between actin 
and myosin, whose attachment and movement result in muscle contractions.73,74 
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The functionality of proteins means that they have roles in almost all biological functions: 
from the translation of DNA and RNA to proteins (various RNA synthetases, individual ribosome 
components), to cellular processes (respiration, membrane channel transport), to cell to cell 
signaling (Human Growth Hormone, insulin), to digestion (lipases, proteases, amylases) and many 
more. Proteins are also key in the immune system, where antibodies serve as protein markers that 
signal foreign or harmful object to immune cells. By having highly specific interactions with their 
target molecules, antibodies bind to molecules and signal to other systems that said molecules must 
be cleared from the body. These interactions occur not just with antibodies, but also with proteins 
such as Human Serum Albumin, which as discussed earlier, interacts with gp60 in endothelial 
cells,66,67 or Human Transferrin, which interacts with transferrin receptors overexpressed in a 
variety of cancer cells.75 
Many of the above-listed proteins have become therapeutic agents. For example, insulin 
has been used as a treatment to treat diabetes for the last 70 years, and hormone replacement 
therapies are common treatments for glandular pathophysiologies.76 More recent trends in the 
biopharmaceutical industry have focused on the use of antibodies to treat diseases. By using natural 
antibodies, modifying them through genetic engineering methods, or producing de novo 
antibodies,  antibodies can be used to direct the immune system to attack cancerous cells, deliver 
conjugated therapeutics, or affect cellular pathways.77,78 Additionally, there is strong interest in 
using delivery enzymes to treat either generalized deficiencies, or for specific functions, such as 
in reactive oxygen species clearance.79–81 
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1.2.2 Protein Nanoparticles 
Both due to the perceived problems with the EPR effect and proteins’ numerous clinical 
advantages, exploring protein nanoparticles (PNPs) as potential therapeutics seems a sensible next 
step for biomedical research. Traditionally, synthesizing protein nanoparticles occur in one of three 
synthetic methods: nab technology, self-assembly and coacervation. 
 
Figure 1.4 Protein Nanoparticles hold great promise in medicine due to their variety and inherent 
functionalities. Three main methods exist to synthesize these particles. (A) Nab technology works 
by using a sheer mediated process to force hydrophobic drugs within proteins and subsequently 
cause the proteins to aggregate into nanoscale particles. (B) Self-assembly techniques use the 
expression of specially designed proteins by microorganisms that subsequently self-assemble into 
structures that can be used for broad variety of therapeutic applications. (C) Coacervation functions 
by the addition of an organic solvent or reagent to a protein solution, which causes the formation 
of particles that are subsequently crosslinked using bifunctional crosslinkers. 
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1.2.2.1 Nanoparticle Albumin Bound (nab) technology  
Nab technology is one of the oldest and most developed methods for making PNPs. 
Developed by Abraxis Bioscience (now a part of Celgene) to create a way of delivering paclitaxel, 
nab-technology forces highly hydrophobic drugs into the internal hydrophobic pockets of human 
serum albumin (HSA) using a high-pressure manufacturing process. Paclitaxel is normally 
administered using harsh organic solvents.82 By packaging the drug in albumin, a common protein 
in human blood that is not only water soluble but also has a naturally long circulation time, the 
drug can be delivered with reduced side effects.65 The first FDA approved nab product was 
Abraxane, which has been approved for use as a first line therapy for non-small cell lung cancer, 
metastatic adenocarcinoma, and as treatment for metastatic breast cancer. Additionally, Abraxane 
is in Japanese clinical trials by Celgene for use in metastatic pancreatic cancer and gastric 
metastatic cancer.83 
In addition to the success of Abraxane, multiple other nab technologies are under 
investigation at both the industrial and academic level. ABI-008 through ABI-011 are a family of 
nab based drugs that are undergoing clinical trials. For example, ABI-009 (nab-
rapamycin/sirolimus, brand name Tarzifix™) is under investigation by Aadi Bioscience (licensed 
from Celgene) in a variety of phase 1 and 2 trials ranging from Metastatic Colorectal Cancer to 
Pulmonary Arterial Hypertension (see Table 2). In addition to multiple clinical trials, next 
generation nab technologies are actively being investigated. For example, actively targeted 
variants of nab particles have been made. Thao et al. developed nab particles made from 
lactosylated albumin loaded with a mixture of paclitaxel and doxorubicin. The particles were 
designed to take advantage of the high affinity of lactose to asialoglycoprotein receptors, which 
are overexpressed in hepatocellular carcinomas. The particles were shown through in vitro and in 
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vivo experiments to have increased accumulation in liver vs control (Pac/dox loaded into naïve 
albumin nab particles).84 In addition to applying targeting moieties to nab particles, there has been 
work done on the use of adjuvants in potential therapies. An interesting case was the work 
performed by Kinoshita et al, where Abraxane was delivered with S-nitrosated HSA dimers.85 By 
modifying the HSA dimer through a vasodilator. This effect increased the delivery and efficacy of 
Abraxane in colon cancer and melanoma murine models, and reduced metastases. Creative 
combinations of therapies such as this show potential translatability in that they follow the 
pharmaceutical industry model of expanding the potential of a therapy through combination 
studies. 
While showing great potential, nab technologies have potential downsides. Early work has 
shown that Abraxane is associated with more rapid plasma clearance compared to the traditional 
liposomal formulation of paclitaxel (Taxol).64 Abraxane nanoparticles are stable in ex vivo saline 
solutions, but the particles quickly break down into albumin-paclitaxel complexes following 
administration.65 This poor colloidal stability has been suggested as the reason behind the rapid 
clearance of the nanoparticles.86 Work has been done to improve the colloidal stability of nab 
particles,86,87 but these works have used albumin bound paclitaxel particles made through 
coacervation techniques, not high pressure homogenization as Abraxane and other nab particles 
are. Further studies are therefore needed to substantiate claims of improved stability. This problem 
of using coacervation synthesized particles as a stand-in for Abraxane has also been seen in other 
studies with potentially impactful advances.88,89 In addition to poor clearance profiles, nab 
technology has the inherent downside of harsh synthetic conditions.90 This potentially limits the 
use of nab technology to deliver active proteins, such as enzymes, in ways that other synthetic 
routes that are able to.91 Excellent reviews of nab technologies have been written by Hawkins et 
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al. and Tan et al., among others, which we recommend for further reading.92,93 Nab technology 
has shown the clinical potential of proteins as nanocarriers in medicine. 
1.2.2.2 Self-assembled protein nanoparticles  
Self-assembled nanoparticles are nanoscale structures made of protein complexes that can 
self-assemble to form PNPs. These structures are designed by creating recombinant proteins that 
contain oligomerization-domains that create structure, and then a variety of other domains that can 
result in specific activity.94  The synthetic methods and design strategies for nanoscale protein 
structures have been excellently summarized in recent reviews.94,95 
An interesting application of self-assembled PNPs in the medical space is the use of caged 
protein nanoparticles.96 These particles are made up of protein units that self-assemble under 
specific conditions into hollow cage-like structures. Inside these structures it is then possible to 
load a variety of therapeutic molecules such as enzymes97 and small molecules.98 In a recent study, 
Kawakami et al. designed a 60-mer protein cage with a defined structure. Notably, they were able 
to design the particle so that specific residues faced either the exterior or interior of the cage, and 
subsequently were able to covalently modify these particles.99 These covalent modifications were 
done using disulfide bonds, and thus this system could be designed to carry a drug in the inside of 
the cage, and then be released in a reducing environment.  
These self-assembled nanoparticle technologies are elegant, sophisticated, and 
complicated. However, these very characteristics call into question their potential for translation 
to the clinic in the near future. Most of the proteins used in these nanoparticles are not only novel 
recombinant proteins, but are also expressed in non-mammalian organisms such as Escherichia 
coli.99 Expression in non-human organisms of recombinant proteins presents many regulatory 
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problems and costs, as has been shown though the past 30 years with the rise of recombinant 
antibody and antibody fragment (Fab) technology.100 Yet, with careful development, the rise of 
the multibillion-dollar biological therapeutics field shows the potential for progressively more 
sophisticated therapies to eventually enter the market. 
1.2.2.3 Coacervation-synthesized protein nanoparticles 
During coacervation, a “coacervation agent”, usually an organic solvent such as acetone or 
ethanol, is added to a concentrated aqueous solution of a protein of interest. The coacervating agent 
dehydrates the proteins and causes the precipitation of nanoparticles from the solution. The 
particles can then be crosslinked, rendering them water insoluble. By controlling a variety of 
conditions, including the protein type, the rate of addition of the coacervating agent, the 
temperature of the procedure, the salt content of the solution, and the crosslinking agent and time, 
the resulting nanoparticle size, mechanical properties, and functionalities can be tailored to fit the 
needs of the application.101,102 In addition, the process is highly reproducible, and the particles can 
be surface functionalized and loaded with a variety of therapeutics.103–105 
Initial work using coacervation focused on albumin proteins, but the field is now expanding 
to a variety of different proteins and applications. A wide variety of different proteins have been 
formulated into nanoparticles, as detailed in a recent review.106 These proteins have been used in 
applications such as the packaging of small molecules and micro-nutrients for the food industry. 
Guo et al. produced whey protein nanoparticles loaded with zinc and showed that particle size 
could be controlled by modulating the amount of zinc added and the synthesis conditions. 
Additionally, they showed through in vitro experiments that site specific delivery of zinc was 
possible by pH dependent release of the micronutrient from the PNPs to its nutritionally relevant 
site, the intestinal track, as opposed to the stomach.107 
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Through coacervation techniques, PNPs have been prepared from a wide variety of 
polypeptides and proteins for therapeutic purposes.91,108,109 A recent publication that used the PNP 
technologies developed by the Champion lab demonstrated a proof of concept of a universal 
influenza virus.110 Nanoparticles were comprised of a core of a tetramer of M2e epitopes from four 
influenza subtypes, and surface modified with one of two different recombinant mutants of the 
highly conserved hemagglutinin (HA) stalks from various subclasses of influenza. By creating a 
cocktail of two nanoparticles, each modified with different recombinant HA variants, Deng et al. 
elicited universal protection to a wide variety of influenza subtypes. While the use of the highly 
conserved M2e epitopes has been attempted before in vaccines, these vaccines were constructed 
from virus-like particles (VLP) loaded with epitopes and resulted in off target immune responses 
due to the carrier proteins in the VLP.111,112 PNPs made almost entirely of proteins of interest, as 
was demonstrated in the work by Deng et al., can avoid off target effect problems. Additionally, 
coacervation-manufactured PNPs, as opposed to the self-assembled or VLP counterparts, have 
greater stability over a large range of physiological environments, and studies have shown that 
they can potentially create cold chain-independent therapies.113 A clear downside of coacervation 
particles is inherent in the simplicity of their synthetic method, in that it creates homogeneous 
distributions of proteins throughout each particle. Only radial complexity through surface 
modifications methods are able to provide any kind of anisotropy to the particles, as opposed to 
technologies that will be presented in this thesis.  
Knowledge of protein folding and biochemistry has advanced to the point where novel 
structures and functions can be built de novo through either first principles engineering, as 
demonstrated in a variety of self-assembled nanoparticles previously described, or through 
directed evolution, as has been seminally shown by the work of Frances Arnold and colleagues.114 
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However, the use of novel proteins does raise questions of translatability of technologies that are 
based on almost entirely recombinant proteins and have no analogues in the clinic or even the 
human body. Additionally, new proteins offer the ability to potentially use the function-follows-
form principles of proteins to build complex, compartmentalized nanomachines from protein 
nanoparticles, though this possibility has yet to be fully explored. The large number of different 
synthetic routes, functionalities and applications of nanoparticles based on proteins as their 
building blocks that have been recently developed and commercialized shows the bright potential 
for PNPs as a revolutionary form of nanoparticles in medicine However, more generalizable 
synthesis techniques will be needed to allow mass production of PNPs, potentially if they are multi-
functional and thus require more control over anisotropy during production. 
 Electrohydrodynamic Co-jetting 
1.3.1 Synthesis of NPs Using Electrohydrodynamic Co-jetting  
The Lahann group has developed over the last 10+ years a technique for synthesizing 
multicompartmental NPs.115–117 Electrohydrodynamic (EHD) co-jetting functions by dissolving a 
polymer in an appropriate solvent and then pressure driving said polymer at a low flow rate through 
a syringe, creating a droplet on the tip of a needle attached to the syringe. A high voltage is placed 
between this syringe and a collecting surface, causing an electromagnetic pulling effect on the 
droplet. A Taylor cone is formed at the end of the droplet, breaking the surface tension at a focused 
point (Figure 1.5). This breaks apart the droplet, sending either small particles or fibers (micron 
to nanometer range) to the grounded collecting surface. The creation of particles (Figure 1.5A) or 
fibers (Figure 1.5B), and their respective characteristics, is dependent on a wide range of 
parameters, namely applied voltage, dielectric constant and volatility of the solvents, total viscosity 
of the solution, the length of the polymer chains, distance between the needle and collector, type 
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of collector used, flow rate, and needle gauge. While in midair transit, the small size of the created 
structures causes near instantaneous solvent evaporation, leaving dry product on the collecting 
surface.118 
 
Figure 1.5 Electrohydrodynamic jetting can synthesize micro and nanoscale (A) particles or (B) 
fibers out of a variety of different materials. 
Through the use of a parallel, laminar flow needle setup, it is then possible to create 
multicompartmental particles that are made of distinct volumes, each of which can be composed 
of different base polymers (synthetic and natural), and loaded with various small molecules 
(therapeutics, contrast agents), inorganic, and biological compounds (RNA, peptides) (Figure 
1.6).119 
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Figure 1.6 EHD co-jetting can make anisotropic micro and nanostructures by using parallel 
capillaries. Adapted from refs.115,119 
1.3.2 Applications of EHD Co-jetting 
First developed in 2004 as a method to synthesize polymer-based particles with distinct 
phases,115 EHD co-jetting has evolved into a robust method to produce micro and nanostructures 
for various biomedical applications. Beyond microparticles, it is now possible to create micro-
fibers, rods and cylinders, disks, and nanoparticles, all with anisotropic features and controllable 
sizes.117,119 Improvements in controlling the electric fields have made it so that complex scaffolds 
made of precisely placed microfibers can be made at large scale.120 The process has also been 
scaled up for large scale manufacturing of fibers and particles.121 
Methods have also been developed for transforming the structures from inert to functional. 
By including polymers with different functional groups in each compartment, orthogonal 
chemistries can be used to place different chemical entities, such as proteins, targeting ligands, and 
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polymer brushes on the surfaces of said compartments (Figure 1.7).122–124 For example, these 
orthogonal chemistries were used to attach Plexiafor, a targeting molecule that specifically homes 
to the cell surface receptor CXCR4, which is overexpressed in triple negative breast cancer, onto 
the surface of one compartment of nanoparticles. These particles were then selectively taken up 
by CXCR4 cells.125 
 
Figure 1.7 EHD co-jetting has been used for a variety of applications. (A) Microcylinders that use 
cardiomyocytes to self-actuate. (B) Triple-negative breast cancer targeting microcylinders. (C) 
Multicompartmental microparticles with chemically orthogonal surface modifications. Adapted 
from refs.122,123,125 
In addition to surface modification, medically relevant molecules can be independently 
loaded into each compartment of the structures to allow for the loading of incompatible entities 
into single particles. This allows for applications such as in theragnostics, where single particles 
are used both for therapeutic and diagnostic purposes, such as in work by Misra et al., where 
particles were constructed to deliver both si-RNA and an imaging agent.126 Since particles can be 
made of different base polymers, this also allows for the control of release dynamics of therapeutics 
from each compartment. Rahmani et al. demonstrated this ability by constructing a microparticle 
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system where the chemotherapeutic drug irinotecan was loaded in a two compartment 
nanoparticle, where one compartment would detect low pHs, such as those inside cells or in cancer 
environments, and quickly release its irinotecan payload over a period of 10 hours, while the other 
compartment would slowly release the irinotecan load over a 5 day period.127 
 Aims of this Work 
In this dissertation, electrohydrodynamic (EHD) co-jetting is used to develop a new flexible 
methodology to create protein based nanocarriers. Synthetic Protein Nanoparticles (SPNPs) are 
composed of i) a protein or proteins of choice and ii) a macromer that reacts with proteins to hold 
them together. The work herein builds upon the groundwork protein-based nanoparticles 
developed previously and expands a technology that was based on a single protein and inert 
macromer into a design space that allows for a wide variety of proteins and functional macromers. 
To show how SPNPs could be used not just as inert carriers, a method to load active enzymes into 
the particles was developed. Additionally, as SPNPs are still in the pre-clinical stage, a 
microfluidic method to characterize the particles based on material composition was developed to 
facilitate future scale up. Lastly, preliminary work was conducted on developing additional 
applications of SPNP technology for neuroblastoma targeting and gene delivery. 
Aim 1: To develop SPNPs into a modular system that allows for a choice of protein, 
macromer, and geometric composition. Here, the design space of current SPNP technologies in 
terms of protein and macromer choice is expanded. The biological behavior effects of SPNP 
material choices is explored, and SPNPs made of two compartments are characterized. 
Aim 2: To apply SPNPs to active enzyme delivery. Enzymes are some of the most medically 
useful types of proteins. A method to load active enzymes into SPNPs was developed. Loading, 
processing, and storage effects of activity in enzyme loaded SPNPs were then characterized. A 
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method to target SPNPs to specific tissues was developed and their use in an in vitro disease model 
demonstrated. Last, the behavior of bicompartmental SPNPs loaded with complimentary enzymes 
in each compartment was explored. 
Aim 3: To apply Electrokinetic microfluidic devices to characterize multi-protein SPNPs. If 
SPNPs are eventually developed for clinical used, high throughput characterization methods will 
be needed for effective manufacturing. Here, we first design and synthesize a multiprotein SPNP 
system for characterization in electrokinetic microfluidics. With these particles, we were able to 
characterize and differentiate between single protein, single compartment protein blend, and two 
compartment SPNPs using electrokinetic microdevices. 
Specific Aim 4: To explore further applications for nanomedicine for cancer therapeutics. 
SPNPs also show promise for in targeted delivery using small molecule targeting ligands. For this 
purpose, the use of meta-iodobenzylguanidine (MIBG) as a targeting moiety in neuroblastoma was 
developed, using poly(lactic-co-glycolic acid) as the material for nanoparticles, and key 
information about the chemical behavior of MIBG for targeting purposes was discovered.
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Chapter 2 
Preparation of Synthetic Protein Nanoparticles 
 
Part of the material for this chapter has been adapted with modifications from the following 
publication: 
 
1. D. F. Quevedo*, N. Habibi*, J. V. Gregory, Y. Hernandez, T. D. Brown, R. Miki, B. N. 
Plummer, S. Rahmani, S. Mitragotri, and J. Lahann, “Multifunctional Synthetic Protein 
Nanoparticles” In Preparation. *equal contribution 
 
 Background and Motivation 
Nanoparticle-based drug delivery systems provide improved drug stability, reduced drug 
toxicity and improved biodistribution compared to free drugs.128–130 There are a number of 
nanoparticle therapeutic platforms such as PEGylated liposomal doxorubicin (Doxil) and 
liposomal vincristine (Marqibo) that have been approved for cancer treatment.48,131. Despite the 
progress made in the field of nanoparticle-based drug delivery, there are still unmet challenges, 
like poor circulation times due to immunogenicity and a lack for adequate functional 
materials.132,133 Solutions to these challenges often conflict with each other, leading to the 
development of multifunctional, multicompartmental nanoparticles.117 Multifunctional 
nanoparticles have traditionally been made of synthetic polymers, such as polyethylene glycol 
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(PEG),134 poly(lacticde-co-glycolide) (PLGA),135 or block copolymer systems.136 Using proteins 
as the primary building block of nanocarriers could be an appealing alternative, because of their 
chemical diversity, inherent biological functions, and a potentially reduced risk for 
immunogenicity.137  
Protein nanoparticles (PNP)132,137 have been pursued for drug delivery applications including 
the clinically approved drug Abraxane64 and other preclinically studied candidates.138–140 Common 
PNP fabrication methods include, among others, nab technologies,84,88 coacervation,91,101 and self-
assembly.99,141 Despite undoubtable progress in recent years, PNP technologies are still hampered 
by a range of drawbacks. While PNPs prepared via nab technologies have been implicated with 
decreased morbidity,142 the processing conditions during particle preparation have been showed to 
cause protein denaturation.143 Coacervation can create large quantities of PNPs,103 but generally 
lacks sufficient control to prepare multifunctional nanoparticles. Self-assembly can provide more 
structural diversity,95 but requires ab initio design of new protein building blocks that has to be 
done separately for each application. Except for the more involved self-assembly route, none of 
these techniques has so far resulted in architecturally controlled protein nanocarriers, such as bi- 
or multicompartmental nanoparticles.  
Electrohydrodynamic (EHD) co-jetting has previously been shown to be effective at creating 
multicompartmental particles with nanoscale anisotropy.144 EHD co-jetting relies on laminar co-
flow of two or more polymer solutions prior to the jet ejection to pre-template compartmentalized 
nanoparticles and nanofibers, with fine control over size, shape, composition, and spatial 
distribution of matter at the surface and bulk level.145,146 EHD co-jetting has been used to fabricate 
multicompartmental polymer particles that incorporate various functionalities, such as stealth 
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modalities,147 targeting/tracing,148 and encapsulation of different cargos such as siRNA,149 imaging 
agents,150 and small molecule cancer drugs.151  
As traditional protein nanoparticle synthesis methods lack control over anisotropy, we have 
developed reactive electrojetting as a method for making anisotropic Synthetic Protein 
Nanoparticles (SPNPs). Reactive electrojetting takes advantage of the anisotropic control afforded 
by EHD co-jetting to create protein nanoparticles, and then introduces a second chemical step that 
converts the particles into nanogels through a sol-gel transition using a variety of macromers.  
 Methods 
2.2.1 Materials 
Recombinant Human Serum Album (Cellastim S) was purchased from InVitria. Human 
Transferrin, Human Hemoglobin, Lysozyme, Horseradish Peroxidase, Human Recombinant 
Insulin, 2KDa O,O′-Bis[2-(N-Succinimidyl-succinylamino)ethyl]polyethylene glycol (PEG-
NHS) or 4,7,10,13,16,19,22,25,32,35,38,41,44,47,50,53-Hexadecaoxa-28,29-
dithiahexapentacontanedioic acid di-N-succinimidyl ester (PEG-NHS-S) were acquired from 
Sigma Aldrich. All buffers, purchased in solution form, and all other reagents used were of lab 
grade and acquired from Sigma Aldrich or Thermo Fisher. 
2.2.2 Electrohydrodynamic Co-jetting 
All SPNP types were synthesized using EHD jetting, with differences in the protein 
solution used and subsequent processing resulting in different copolymer SPNPs. In general, the 
EHD jetting method was done as previously described,122,123,152,153 here a protein solution is 
pressure driven through a 25G blunt tip needle at a flow rate of 0.1 mL hr-1, and a sufficient voltage 
applied between the needle and a collecting surface to produce a stable Taylor cone. The voltage 
causes the droplet to be pulled towards the collecting substrate, and the stream subsequently breaks 
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up into nanometer sized spheres. In mid-flight, the solvents rapidly evaporate to form solid 
nanoparticles. For fluorescent tagging, BSA-Alexa Fluor dyes were incorporated into the protein 
solution at a concentration of 0.8% (w/w) of the total mass of protein unless otherwise noted. 
2.2.3 SPNP Synthesis Using PEG-NHS and PEG-NHS-S 
For SPNPs made with ester-based macromers, a protein solution was made by fully 
dissolving a protein of interest at 10% w/v in a 90:10 (Ultra-Pure H2O:EtOH) solution. Depending 
on the method, PEG-NHS or PEG-NHS-S was added at 10% (w/w of protein mass) to the solution. 
After EHD jetting, the nanoparticles were placed in a dry 37 °C oven for 7 days, and subsequently 
collected by scraping them off the collection surface using a solution of DPBS supplemented with 
0.01% Tween 20. 
2.2.4 SPNP Synthesis Using GA 
To synthesize SPNPs polymerized with vapor-phase Glutaraldehyde (GA), a protein 
solution was made by fully dissolving a protein of interest at 10% w/v in a 90:10 (Ultra-Pure 
H2O:EtOH) solution, without macromer included in the jetting solution. After EHD co-jetting the 
resulting particles were incubated at room temperature in a closed container, which contained 
2.5mL of 20% Glutaraldehyde in a plastic reservoir, for 30 minutes. The unreacted glutaraldehyde 
was quenched by collecting the particles by scraping them off the collecting surface using Ultra-
Pure H2O supplemented with glycine (100 mM) and 0.01% Tween 20. 
2.2.5 SPNP Synthesis Using S-S 
SPNPs synthesized through oligomer-free disulfide bonds (S-S) were made by dissolving 
the protein of interest at 2.5% w/v in a 90:10 (2,2,2-Trifluoroethanol: Ultra-pure H2O) solution, 
and the protein allowed to denature for 2 hours in order to fully break all disulfide bonds. 2-
Mercaptoethanol was then added at a 10x molar excess to the number of disulfide bonds in the 
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protein and allowed to incubate for 30 minutes at room temperature. The solution was then jetted, 
and the resulting particles collected as previously described. 
2.2.6 Nanoparticle Collection 
After collection, the collected solution was sonicated on ice, run through a 40 μm cell filter, 
and then centrifuged at 3,200 rcf for 5 minutes to remove large particles. The resulting supernatant 
was then centrifuged at 21,130 rcf for 40 minutes to collect the desired particles. The final particles 
were washed at least 5 times through centrifugation using DPBS supplemented with 0.01% Tween 
20. 
2.2.7 Nanoparticle Characterization 
Particles, prior to collection, were imaged using Scanning Electron Microscopy (Thermo 
Fisher Nova 200 Nanolab Dualbeam FIB). Particle diameters were measured using an automated 
MATLAB macro based on the function ‘imfindcircles’, and the resulting diameters converted to 
frequency histograms using GraphPad. To determine their hydrodynamic size distribution after 
isolation, the particles were suspended in 0.22 μm filtered DPBS supplemented with 0.01% Tween 
20, sonicated on ice, and measured using dynamic light scattering (Malvern ZSP ZEN-5600). 
Standard settings were used and an average of three measurements are reported. Particle zeta 
potential was measured on the same instrument using a disposable folded capillary cell (DTS1070, 
Malvern) and using standard settings. Particle concentration was measured using a BCA assay, 
using a BSA standard for a standard curve. Particle number concentrations were measured using 
Nanoparticle Tracking Analysis on a Malvern Nanosight. 
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2.2.8 CD Spectroscopy 
Circular Dichroism (CD) Spectroscopy was used to study the effects of EHD jetting on the 
proteins that compose SPNPs prior to polymerization. Fully synthesized SPNPs were not studied 
using CD spectroscopy due to the method’s inability to obtain measurements that can be analyzed 
with deconvolution based secondary structure analysis from aggregated protein complexes.154 The 
different methods used to polymerize the SPNPs were carried out, without the corresponding 
macromers, for the NHS-PEG, NHS-PEG-S and GA macromers. As S-S crosslinking occurs 
during  immediately during the jetting process, it was not possible to quantitatively study the effect 
of jetting on the proteins, but since the process for S-S includes purposeful denaturation of the 
proteins with a strong organic solvent and a reducing agent, it stands to reason that little to one of 
the original secondary structure would be maintained after the jetting process.  
Particles were jetted, but no macromers were included in the jetting formulations or post-
jetting. The particles were then treated identically as if they would have been had macromers were 
included, with incubation at 37°C for 7 days for PEG-NHS based macromers, and storage at 4°C 
overnight for GA treated SPNPs. After treatment, the particles were collected and treated following 
protocols for secondary structure analysis based on deconvolution of CD signals.155 Briefly, the 
particles were collected using a 10 mM Potassium Phosphate, 100 mM potassium fluoride (pH: 
7.4) buffer. The collected solution was filtered using a 0.22 μm syringe filter, and the protein 
concentration measured using a Nanodrop 2000c Spectrophotometer (Thermo Fisher Scientific), 
with the absorption at 280 nm measured and converted to mass concentration using an extinction 
coefficient of 85.1 M-1cm-1.156  
The samples were then diluted to a concentration of 0.15 mg/mL in the same buffer 
described previously and measured in a 0.1 cm pathlength Hellma quartz cuvette in a Jasco J-815 
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CD Spectrometer. Temperatures were controlled using a Peltier stage. Spectra were acquired at a 
stage temperature of 20 °C from 185-260 nm, using a data pitch of 0.2 nm, a digital integration 
time of 1 sec, bandwidth of 1 nm, and a scan speed of 50 nm/min. Each sample was measured for 
a total of 10 accumulations and was smoothed using Savitzky-Golay algorithm (Convolution 
Width of 21) and normalized to the buffer. Native and denatured proteins were measured by 
dissolving protein in the same buffer as the nanoparticle samples. A thin layer of mineral oil was 
placed atop the sample to reduce evaporation, and the sample was measured at 20 °C for the native 
protein control measurement. The sample was then heated to 90 °C and subsequently allowed to 
equilibrate for 5 min prior to measurement for the denatured sample. The smoothed signals were 
analyzed for secondary structure using DichroWeb.157–161 
2.2.9 Cell Culture 
HeLa cells (ATCC) were grown at 37 °C in a humidified environment at 5% CO2. Cells 
were cultured in DMEM media supplemented with 10% fetal bovine serum (FBS), 1% Non-
essential Amino Acids (NEAA), D-glucose (25 mM), and Sodium Pyruvate (1 mM). Cells were 
passaged at 70-80% confluence and media changed as needed. 
2.2.10 Confocal Microscopy 
HeLa cells were seeded in 8 well chamber slides at a concentration of 50,000 cells per well 
and allowed to adhere overnight. SPNPs were sonicated in ice, and immediately added at a 
concentration of 10 μg mL-1 to cell media supplemented with penicillin (100 Units mL-1), 
streptomycin (100 μg mL-1), and Amphotericin B (250 ng mL-1). Cells were incubated with the 
particles for 1 hr. Particle media was removed following incubation, and the cells thoroughly 
washed with DPBS. Cells were fixed with 4% paraformaldehyde, washed with DPBS, and then 
stained with Alexa Fluor 488 Phalloidin following manufacturer recommendations. The samples 
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were then air dried, mounted using ProLong Diamond Antifade Mountant with DAPI, and allowed 
to cure for 24 hr prior to imaging. Confocal micrographs were obtained using a Nikon A1si 
inverted confocal microscope. A 60X water objective with excitation at 401, 488, and 641 nm for 
the cell nuclei, actin fibers, and SPNPs, respectively, was used for image acquisition. NIS-
Elements and ImageJ software was used for image acquisition and processing. 
2.2.11 Flow Cytometry 
HeLa cells were seeded in a 96-well plate at a density of 30,000 cells per well. After 
overnight incubation at 37 °C and 5% CO2, the media was then removed from the wells, and fresh 
media containing each SPNP group at 10 μg mL-1 was added to the wells. The cells were incubated 
with SPNPs for 24 hr. The cells were washed with DPBS three times and then trypsinized. The 
cells were washed two more times and stained with DAPI before analyzing them with Cytoflex 
(Beckman Coulter) cell analyzer located at the Flow Cytometry Core of the University of 
Michigan. FlowJo software was used for data analysis. Statistical analysis was conducted using a 
one-way ANOVA, followed by Tukey’s post-test, using GraphPad software. A P-value of <0.05 
was considered statistically significant (*P<0.05, **P<0.01, ***P<0.001; ****P<0.0001). 
2.2.12 Blood Brain Barrier Transwell Assay 
For particle transport studies, 5E10 NP/mL Human Transferrin (hTf)- and Human Serum 
Albumin (HSA)-SPNPs were prepared in complete cell culture media and added to the apical 
compartment. The companion plate in the basolateral compartment contained only complete 
culture media. At each hour timepoint for 6 hr, a 100 μL aliquot was sampled from the basolateral 
compartment and pipetted into a 96-well plate. Fresh complete cell culture media (100 μL) was 
immediately added to the basolateral compartment upon removal. Fluorescence intensities of 
samples obtained from the basolateral medium upon 1 hr, 2 hr, 3 hr, 4 hr, 5 hr and 6 hr intervals 
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were measured in triplicate using the BioTek Synergy H1 Hybrid Multi-Mode Microplate Reader. 
Solute concentration was determined based on calibration curves of standard fluorescence 
intensities created in triplicate. Percent (%) transport of SPNPs were then calculated. 
2.2.13 Bicompartmental SPNP Synthesis 
Bicompartmental SPNPs were synthesized using GA as a macromer but using a parallel 
capillary EHD co-jetting setup previously described.122,123,152,153 
2.2.14 Structured Illumination Microscopy 
Anisotropic SPNPs (ASPNPs) with two compartments were synthesized as described 
above using HSA and hTf. To facilitate imaging of the resulting particles, BSA Alexa 488 and hTf 
Alexa 647 were incorporated, at 0.08% (w/w) of the total protein mass, into the albumin and 
transferrin protein jetting solutions, respectively. GA was used to crosslink the resulting ASPNPs. 
Albumin-transferrin ASPNPs were collected and purified as previously described and finally 
suspended directly in Prolong Diamond before being deposited onto glass slides. Samples were 
allowed to cure for at least 24 hr prior to imaging. Structured Illumination Microscopy (SIM) 
imaging was conducted using a Nikon N-SIM +A1R confocal microscope equipped with a 100X 
oil objective. Excitation using the 488 and 647 nm lasers were used for image acquisition. Three-
dimensional z-stacks of multiple regions were collected and deconvoluted using the Nikon 
Elements software. The resulting z-stacks were analyzed to confirm bicompartmental particle 
architecture. 
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 Results and Discussion 
 
Figure 2.1 (A) Preparation of Synthetic Protein Nanoparticles (SPNPs) using 
Electrohydrodynamic jetting. (B) SEM images of particles made using EHD jetting. Particles are 
jetted, and subsequently (C) polymerized using a variety of different macromers.  
To prepare SPNPs using reactive electrojetting, particles are first made using EHD jetting. 
Protein was dissolved in an aqueous solvent system with 10% ethanol. The addition of an organic 
solvent increases the volatility and decreases the surface tension of the solution.162 Solid 
nanoparticles are then prepared by accelerating the jetting solution in an electrical field created 
between the tip of the jetting needle and a collection plate (Figure 2.1A). Once the electrical 
potential is applied, a Taylor cone is spontaneously formed,163 and the jet is ejected from the Taylor 
cone towards the collection plate. In EHD jetting, conditions (i.e. surface tension, flow rate, solute 
concentration, applied electric field) can be controlled to result in either particle formation or fibral 
formation. The protein concentrations in all jetting solutions were maintained 10% (w/v) or lower 
to ensure that only particles were formed. After EHD jetting, particles were examined for 
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uniformity and sphericity using Scanning Electron Microscopy (SEM) (Figure 2.1B). Circular 
Dichroism (CD) spectroscopy demonstrated that component proteins had unchanged secondary 
structures compared to their native confirmations (Figure 2.2, Table 2.1). 
 
Figure 2.2 The effect of EHD jetting on proteins was analyzed using Circular Dichroism (CD) 
Spectroscopy. Transferrin was jetted and treated as described in the text but did not include 
macromer for NHS-PEG and NHS-PEG-S (purple) or GA (green). Native (black) and heat 
denatured transferrin (pink) were measured as controls. 
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Table 2.1 measured CD spectra for free transferrin controls and analogues for methods 1-3 were 
deconvoluted using the different algorithms and neural networks available in Dichroweb. For all 
but the denatured transferrin, most of the algorithms were able to fit the measured signals within 
high degrees of certainty, and the ratios of secondary structures were similar to those found using 
X-Ray crystallography (from PDB). Additionally, the ratios found for all algorithms matched 
almost identically for the different polymerization methods studied. 
Sample Sample  Treatment Structure X-Ray Selcon3 Contin-LL CDSSTR K2d 
Free 
Transferrin 
Native 
α-Helix 0.34 0.29 0.25 0.24 0.29 
β-Sheet 0.19 0.24 0.27 0.30 0.27 
Turn 0.22 0.23 0.23 0.22 ND 
Unordered 0.25 0.28 0.26 0.26 0.43 
Denatured 
α-Helix 
NA 
0.07 0.15 0.06 0.09 
β-Sheet 0.32 0.32 0.33 0.39 
Turn 0.19 0.23 0.27 ND 
Unordered 0.30 0.30 0.33 0.52 
Jetted 
Transferrin 
Methods 1 and 2 
α-Helix 
NA 
0.25 0.25 0.24 0.29 
β-Sheet 0.24 0.27 0.28 0.30 
Turn 0.23 0.22 0.22 ND 
Unordered 0.28 0.26 0.26 0.41 
Method 3 
α-Helix 
NA 
0.25 0.25 0.24 0.29 
β-Sheet 0.24 0.27 0.28 0.30 
Turn 0.23 0.22 0.22 ND 
Unordered 0.28 0.26 0.26 0.41 
 
The second step of reactive electrojetting is the reaction of the proteins in the nanoparticles 
with a variety of reactive macromers, such as short NHS-ester functionalized polyethylene glycol 
(PEG) chains (Figure 2.1C). The reaction occurs during or immediately after the EHD jetting 
process, rendering the SPNPs stable in aqueous environments and locks in their geometry. A small 
library of commercially available macromers was selected to investigate different sol/gel 
transitions. The first two macromers, PEG-NHS and PEG-NHS-S, react the macromers’ ester 
functional groups with the proteins’ amine groups. This reaction completes after SPNPs are 
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deposited by EHD jetting onto the collecting surface and then placed at 37 °C for 7 days. The third 
macromer, GA binds proteins together by reacting aldehyde groups with a variety of protein 
residues.164 GA crosslinking is conducted immediately after EHD jetting, when dried protein 
particles are placed in a sealed container containing 20% glutaraldehyde, which vaporizes and 
reacts at room temperature. The last crosslinking method does not rely on a macromer but instead 
takes advantage of native disulfide bonds within proteins (S-S). Prior to EHD jetting, proteins are 
treated by Trifluoroethanol (TFE) to break intra-protein disulfide bonds, and with β-
mercaptoethanol (BME) to inhibit spontaneous reformation of disulfide bridges from resulting free 
thiols. The solution is then jetted as described previously. While droplets are traveling to the 
collecting surface, TFE and BME evaporate allowing the disulfide bonds to reform between 
proteins, resulting in insoluble SPNPs on the collecting surface. 
PEG-NHS was selected as a biocompatible and biodegradable macromer that can be 
imparted with functional groups. PEG-NHS-S showcases the flexibility of macromers based on 
PEG-NHS. By incorporating stimuli responsive groups into the PEG chain, such as the disulfide 
in the PEG-NHS-S, particles can be made to react differently to different environments. GA vapor 
treatment was developed as a faster alternative to PEG-NHS macromers, as the vapor-phase 
reaction occurs in as little as 30 minutes to form fully water insoluble SPNPs. Thus, GA allows 
for the incorporation of time sensitive agents into SPNPs, such as radiotherapeutics. S-S was 
developed to have a method which does not use any available functional groups on the protein 
residues, unlike the three other macromers. Additionally, S-S takes place in an organic solvent 
system, as opposed to the aqueous system used for the other macromers. This different solvent 
system introduces the ability for SPNPs to be loaded with hydrophobic drugs, opening up a large 
number of potential therapeutics for drug delivery with SPNPs. 
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Figure 2.3 Histograms of diameters measured by SEM. SEM micrographs of SPNPs made using 
(A) Insulin, (B) Hemoglobin, (C) Lysozyme, and (D) Transferrin were measured using an 
automated MATLAB program. 
After the reactive electrojetting process, the resulting particles have a broad size distribution 
as seen by SEM (Figure 2.3). To further narrow particle size distribution, particles were first 
collected, then sonicated to cause disaggregation, and were size purified using a previously 
established serial centrifugation technique.150 After hydration, particles made with hTf and each 
of the different macromers were measured using Dynamic and Electrophoretic Light Scattering 
(DLS and ELS), and found to have similar size distributions and zeta potentials (Figure 2.4). 
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Figure 2.4 Different macromers do not significantly change size or zeta potential, and are stable 
over a 1 month period. hTf SPNPs were made with all 4 different macromers, and (A) their sizes 
after synthesis and 60 days later were measured using DLS. Macromers were found to not affect 
particle size, and the particles maintained stability over the time period. (B) The same SPNPs were 
measured using ELS and found to not have significantly different zeta potentials.  
To show how macromer conditions can be used to tailor SPNPs hydrodynamic size, HSA 
particles were made with PEG-NHS. The hydrodynamic size was tuned by changing the macromer 
to protein ratio. Increasing the ratio of macromer to protein does not change the size of particles 
in their dry state, but as the amount of macromer is increased, SPNPs swell less, going from a 
hydrodynamic diameter of 200 nm to 120 nm, when the crosslinker ratio is increased from 10% 
(w/w) to 30% (w/w) (Figure 2.5). 
37 
 
Figure 2.5 Effect of crosslinking macromer on particle size. (A-D) SEM images of SPNPs 
synthesized with various amounts (A) 10, (B) 20, (C) 30, and (D) 40 w/w% of crosslinking 
macromer relative to Human Serum Albumin. (E) Size distribution of SPNPs in their dry state. 
Individual SPNPs (n = 200) measured using ImageJ. No significant difference observed between 
the various formulations. ANOVA, multiple comparisons. (F) Hydrodynamic diameters of the 
resulting SPNPs in PBS measured by DLS, median ± SD. Scale bars = 4 μm 
We also explored how reactive electrojetting can make SPNPs from a variety of proteins. A 
small library of proteins was selected to synthesize SPNPs, each with potential biomedical 
applications: Human Transferrin, 165 Insulin (Ins),166 Hemoglobin (Hem), 167 and Lysozyme 
(Lys).168 For these experiments, each protein was used to fabricate stable SPNPs with PEG-NHS. 
Proteins were dissolved as previously described, with the exception of Ins which was dissolved by 
adding 10% acetic acid to the solvent mixture, due to poor solubility. SEM images of SPNPs as 
sampled from the collecting surface demonstrated that different proteins did not affect the 
morphology of the resulting particles (Figure 2.6A-D) . To evaluate the stability of the particles, 
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SPNPs were collected, size purified, and stored at 4 °C for seven days. Their size distributions 
after a week were similar, confirming particle stability after storage (Figure 2.6E). 
 
Figure 2.6 Stable synthetic PNPs can be made using a variety of proteins. SEM images of SPNPs 
made from (A) hTf-PEG-NHS, (B) Ins-PEG-NHS, (C) Hem-PEG-NHS, and (D) Lys-PEG-NHS. 
(E) The stability of particles in PBS over a 1-week period was characterized by measuring the 
particles using DLS 1 day (blue trace) and 7 days (red trace) after synthesis and size purification. 
Various experiments were conducted to explore how protein and macromer choice affects 
SPNP behavior in biological systems. To investigate the effects of different macromers on the in 
vitro behavior of SPNPs, hTf SPNPs were synthesized with each of the different macromers and 
loaded with fluorescently labeled Bovine Serum Albumin. SPNPs were then incubated with HeLa 
cells. SPNPs behaved differently depending on their macromer. hTf-PEG-NHS and hTf-GA 
SPNPs remained punctate when observed using confocal microscopy (Figure 2.7A and Figure 
2.7B). In contrast, hTf-PEG-NHS-S and hTf-S-S SPNPs, which rely on disulfides-bonds for 
structure, were more diffuse (Figure 2.7C and Figure 2.7D). It is likely that these particles 
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degraded due to disulfide bonds breaking in the cellular oxidizing environment. These effects have 
been observed with other particles made with similar chemical principles.91 
 
Figure 2.7 SPNPs can be made using different methods that have a distinct effect on the in vitro 
uptake and behavior of the particles. (A-D) Fluorescent SPNPs made with macromers were added 
to HeLa cells for 1 hr, and their behavior studied using confocal microscopy. (E) Uptake was 
quantified using confocal microscopy using HeLa cells cultured at equivalent conditions and with 
SPNPs added for 24 hr. (One-way ANOVA). (F) SPNP BBB transport. Percentage transport of 
HSA and hTf SPNS across hCMEC/D3 monolayers in Transwell inserts. (*P<0.05, **P<0.01, 
***P<0.001; ****P<0.0001 
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The uptake of SPNPs was evaluated quantitatively by flow cytometry (Figure 2.7E). There 
was an observed difference in the uptake level for SPNPs based on macromer. Cells incubated 
with hTf-GA showed a 7-fold greater uptake percentage than those exposed to hTf-S-S 
(P<0.0001), and a 2-fold increase compared with hTf-S-S (P<0.0001). Uptake values for cells 
incubated with hTf-GA and hTf-PEG-NHS were not statistically different.  As the particles made 
using different macromers had no significant differences in size distributions or zeta potentials, 
the reasons for these observed differences are yet unknown. We hypothesize that these effects may 
be caused by differences in the secondary structures of the proteins after they undergo 
polymerization after jetting, or in the mechanical properties of the SPNPs, and this will be explored 
in future studies. 
To demonstrate the potential of SPNPs’ variable protein composition biologically, we 
compared the blood brain barrier (BBB) permeability of hTf-PEG-NHS SPNPs to Human Serum 
Albumin SPNPs (HSA-PEG-NHS), which have been previously developed.169 A static in vitro 
BBB model was constructed using a Transwell® migration assay which analyzes cellular transport 
across an analogue of the BBB, where hCMEC and D3 cells are placed in the apical compartment 
.170 SPNPs were fluorescently tagged, and particles that were able to go from the apical to the 
basolateral compartments of the assay were measured using fluorometry. hTf-PEG-NHS SPNPs 
exhibited higher percentage transport across the BBB model, as compared to HSA-PEG-NHS 
SPNPs (Figure 2.7F) as expected, due to the overexpression of transferrin receptors on brain 
endothelium.  
Finally, we sought to demonstrate how reactive electrojetting can synthesize anisotropic 
SPNPs (ASPNPs). Co-jetting is a well-established method where a parallel capillary system is 
used to create laminar flow in EHD jetting.145 To demonstrate that this technology can be applied 
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to SPNPs, particles were made that had one compartment containing fluorescent BSA, and the 
other fluorescent hTf. These particles were processed as previously described and then imaged 
using Structured Illumination Microscopy (SIM). As can be seen in Figure 2.8, the resulting 
particles are clearly composed of two separate compartments that are easily resolved. 
 
Figure 2.8 EHD co-jetting can be used to make bicompartmental SPNPs. (A) SPNPs containing 
Human Serum Albumin (HSA) in one compartment and Human Serum Transferrin (hTf) in the 
other were synthesized, with each compartment doped with BSA-Alexa-488 or hTf-Alexa-647, 
respectively. The particles were imaged using SIM. (B) The images were then deconvoluted. (C-
E) Zoomed in images of individual particles are shown to showcase the bicompartmental nature 
of the particles. 
 Summary 
In this work, we have developed a method for the synthesis of Synthetic Protein Nanoparticles 
fabricated using reactive electrojetting with tunable material compositions. Anisotropic SPNPs 
were also developed. As each compartment can be individually designed, this technique allows for 
the development of complex nanoparticles such that release kinetics of drug cargo from each 
compartment could be independently controlled, as shown in previous studies.127,171 Novel 
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nanoparticle-based cancer vaccines, where each compartment is made of a different cancer 
antigen, could provide significant therapeutic advantages. Additionally, the use of functional 
proteins could also lead to the delivery of active gene therapy enzymes and nucleic acids. Recent 
work has shown how a treatment based on SPNPs cured mice in an intracranial murine model and 
prevented subsequent tumor recurrence from a secondary implant, suggesting immunity to cancer 
recurrence.169 SPNPs have thus already started to demonstrate their potential in both the 
therapeutic and preventive clinical spaces. In the future, we aim to further develop these ASPNPs 
into a variety of clinical applications.
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Chapter 3 
Design of Synthetic Protein Nanoparticles for the Targeted Delivery of Enzymes 
 
Part of the material for this chapter has been adapted with modifications from the following 
publication: 
 
1. D. F. Quevedo, B. Zhang, Y. Hernandez, A. Berardi, R. Miki, J. Lahann, and C. F. 
Greineder “Synthetic Enzyme Nanoparticles Made by Electrohydrodynamic Co-jetting” In 
Preparation. 
 
 Background and Motivation 
Proteins and enzymes are commonly used in the biomedical space. Enzymes, in particular, 
hold much promise, and have been in use therapeutically since the mid-1980s.172 Enzymes have 
many advantages, including high-affinity and specificity to substrates, efficient reaction rates, and 
biodegradability. Enzymes tend to provide more specialized treatments and fewer side effects than 
traditional drugs, as well as an ability to treat deficiency diseases for medical applications.173 While 
enzymes have the potential to revolutionize the therapeutic marketplace, using them in unmodified 
forms has significant drawbacks. In general, there are difficulties in maintaining enzymatic activity 
levels once they are in use, whether it is due to challenges from the immune system or harsh 
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environments upon uptake by cells, both of which could result in enzymatic deactivation or 
destruction.174 
To address these challenges, enzymes can be stabilized and protected using a wide variety 
of techniques.175,176 Medical enzymes are commonly modified by immobilizing them through 
adsorption or covalent bonding onto a solid support or packaging them into solid matrixes.177,178 
Immobilization and encapsulation techniques can improve the thermodynamic stability and thus 
improve performance. Encapsulation of enzymes in nanoparticles holds great promise. Packaging 
enzymes in nanoparticles could potentially increase their long-term stability and circulation time, 
while maintaining their activity, protecting them from degradation, and reducing immunological 
responses.179 
While encapsulating enzymes show much promise clinically, most research has focused on 
using various systems that are impacted by problems with biocompatibility and degradability,180 
including liposomes,181 polymeric nanoparticles,182 sol-gel systems,183 or inorganic based carriers 
such as mesoporous silica,184 magnetic particles,185 or carbon nanotubes.186 As an alternative, 
enzymes encapsulated in constructs that are completely composed of proteins have been 
investigated, such as with Cross-linked Enzyme Aggregates (CLEAs),187 or protein nanoparticles 
synthesized using coacervation.91 However, these synthetic techniques have little capacity for 
customization when it comes to particle compartmentalization, which could open the door for 
particles that have multiple functions that are decoupled from each other or are able to deliver 
multiple incompatible therapeutics. 
A recent advance in nanoparticle technologies has been the use of electrohydrodynamic 
(EHD) co-jetting to make synthetic protein nanoparticles (SPNPs). These particles are made of a 
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system where one component is a protein and the other a macromer, such as an oxidation-sensitive 
PEG chain. The macromers hold the proteins together in a nanoform and can impart the particles 
with additional functionalities, such as environment dependent degradation. SPNPs have shown 
significant promise as a translational therapeutic, as they have been shown to effectively treat 
glioblastoma in a murine model.169 Additionally, particles made using EHD co-jetting are flexible, 
as they can be made from a variety of proteins and macromers, giving them potential for stimuli 
responsiveness and functionality. EHD co-jetting also allows for the formation of anisotropic 
(multicompartmental) SPNPs.188 The flexibility in protein composition gives SPNPs potential for 
the delivery of a wide variety of therapeutics. 
In this chapter, we present the development of enzyme loaded SPNPs generated using EHD 
co-jetting. We have used Catalase (CAT) and Glucose Oxidase (GOX) as proof-of-concept 
enzymes loaded into SPNPs to study the effects of loading on retained activity, show that enzyme-
loaded SPNPs maintain their activity over time, and demonstrate the protection of the loaded 
enzymes from heat denaturation at physiologically relevant temperatures. Additionally, we show 
that we can easily conjugate targeting antibodies onto SPNPs. The antibody-targeted enzyme-
loaded SPNPs show specific uptake, both in cells engineered to express the target receptor and in 
a disease model using primary cells, protecting those cells from ROS damage, and thus 
demonstrating the potential of SPNPs as delivery vehicles for therapeutic enzymes. Last, we show 
that we can make bicompartmental SPNPs that conduct a cascading enzymatic reaction, 
demonstrating the potential to structure enzymes in SPNPs at the nanoscale. 
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 Methods 
3.2.1 Particle Synthesis and Collection 
Particles were synthesized using EHD co-jetting, as previously described. Briefly, a 
solution was prepared that contained a mixture of an enzyme of interest, such as Bovine Liver 
Catalase (Sigma-Aldrich#C40) or Glucose Oxidase (Sigma-Aldrich#G7141), and Human Serum 
Albumin (Cellastim S, InVitria) in a solvent mixture of 90% H2O and 10% Ethanol (v/v%). The 
solution was then pressure driven through a needle at a rate of 0.1 mL hr-1. At the same time, a 
voltage was applied, forming a Taylor cone at the tip of the needle. As the droplet was pulled away 
from the needle, the solvent mixture evaporated, leaving solid nanoparticles which landed on the 
collecting surface. After jetting, the particles were placed in a sealed container with 2.5 mL of 20% 
glutaraldehyde (v/v% in H2O) and allowed to react. Particles were then collected in 100 mM 
glycine solution to quench any unreacted aldehydes. After collection, the particles were sonicated 
on ice and size selected using a modified version of a previously described technique.189 Briefly, 
particles were centrifuged for 1 minute at 3200 RCF to remove large particles. The supernatant 
was then centrifuged first for 5 minutes at 3200 RCF, and the resulting supernatant for 5 minutes 
at 22300 RCF to further fine tune the size of the particles. Lastly, the resulting supernatant was 
then centrifuged for 40 minutes at 22300 RCF in order to isolate the desired particles. The desired 
SPNPs were then washed at least 4 times, followed by decanting and resuspension in DPBS + 0.01 
% Tween 20. 
3.2.2 Particle Characterization (Size, Shape, and Concentration) 
SPNPs were characterized using various techniques to measure their size, shape, and 
concentration. Samples of particles that were jetted onto small silicon wafers were treated with 
vapor-phase glutaraldehyde, gold sputter-coated and imaged in their dry state with Scanning 
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Electron Microscopy (SEM) using a FEI Nova 200 SEM/FIB Microscope. Particle size and zeta 
potential was measured by dispersing hydrated particles in 0.22 μm filtered DPBS + 0.01 % Tween 
20 and measuring them using Dynamic Light Scattering (DLS) and Electrophoretic Light 
Scattering (ELS) (respectively) with a Malvern ZSP ZEN-5600. All DLS and ELS measurements 
are the averages of a minimum of 3 measurement runs. Particle concentrations were measured 
using a Pierce BCA assay, using commercial BSA standards for calibration. 
3.2.3 CD Spectroscopy of Jetted Proteins 
To investigate how electrojetting affects enzymatic secondary structures, SPNPs were 
jetted as previously described, stored over night at 4 °C, and collected using 10 mM potassium 
phosphate, 100 mM potassium fluoride (pH: 7.4) to mimic the crosslinking process. The collected 
solution was then filtered using a 0.22 μm syringe filter, and the protein concentration measured 
by measuring the A280 of the protein using UV-Visible spectroscopy. 300 μL of sample was then 
placed in a Hellma quartz cuvette with a pathlength of 1 mm. The CD spectra from 185-260 nm 
of protein samples was measured using a Jasco J-815 CD Spectrometer. The measurement 
parameters used were a data pitch of 0.2 nm, digital integration time of 1 sec, bandwidth of 1.0 
nm, scan speed of 50 nm min-1, and a sample concentration of 0.15 mg mL-1. Secondary structure 
analysis was conducted with the tools made available by DichroWeb.157–161 Denatured enzyme 
was prepared by heating a sample of native enzyme, in the same conditions described above, to 80 
°C. 
3.2.4 Gel Electrophoresis of Jetted Proteins 
To investigate the consistency between the protein ratio in the jetting solution vs the protein 
ratios in the resulting nanoparticles, SPNPs were jetted as previously described, stored over night 
at 4 °C, and collected as described above without glutaraldehyde treatment. The samples were then 
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analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) stained with 
Coomassie blue. 
3.2.5 Activity Assays of Enzyme Loaded SPNPs 
3.2.5.1 Enzyme Activity Assays 
To investigate the activity of the CAT SPNPs, a previously described hydrogen peroxide 
degradation assay was used.190 Briefly, CAT SPNPs were added to hydrogen peroxide diluted to 
0.036% (w/w) in 50 mM potassium phosphate buffer at room temperature in a quartz cuvette. The 
activity (U/ml) of the SPNPs was calculated using: 
Activity � U
mL
� = 𝑠𝑠 ∗ 2070
∆𝑡𝑡
     (1) 
Where s is the slope of the linear portion of the recorded kinetic measurement, and Δt is the time 
in seconds required for A240 to decrease from 0.45 to 0.40. Duplicate measurements were done per 
sample. GOX loaded SPNPs’ enzymatic activity was assayed using a commercially available assay 
following manufacturer instructions (Abcam, ab219924). 
3.2.5.2 Long Term Activity of SPNPs 
To investigate how enzymatic SPNP activity changed over time, the activity of freshly 
synthesized enzyme loaded SPNPs was measured over a two-week period. Samples were stored at 
either room temperature or 4 °C for the duration of the study. On the day of each measurement, 
the SPNPs were briefly sonicated, diluted, and their activity was measured as previously described. 
3.2.5.3 Activity Stability of SPNPs at Elevated Temperatures 
The enzymatic stability of SPNPs was investigated by measuring their activity after being 
exposed to elevated temperatures. Particles were briefly dispersed using tip sonication, diluted to 
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concentrations appropriate to each activity assay, and then heated at 40 °C for varying amounts of 
time. The tubes were subsequently allowed to come to room temperature and their activity 
measured as described above.  
3.2.6 Surface Modification of Catalase SPNPs 
To conjugate antibodies onto the surface of Catalase-loaded SPNPs, a two-step reaction 
was used. First, a 20x molar excess of Azidobutyric acid NHS ester (Lumiprobe, #63720) was 
added to SPNPs in a 1 mL volume of PBS+ 0.01%Tween, and allowed to tumble and react 
overnight at 4 °C. The particles were then washed 3 times to remove any unreacted Azidobutyric 
acid NHS ester by centrifuging at 23500 RCF for 1 hour, and subsequently resuspending the 
particle pellet in PBS. After washing, the protein concentration was measured using a BCA assay. 
YN1, R6.5, rat IgG, and human IgG were gifts from the Greineder lab. Antibodies were then added 
to the particle solution at a ratio of 2000 Ab per nanoparticle and tumbled overnight at 4 °C to 
react. The number of particles per mass of protein was calculated by measuring a known mass of 
particles by number concentration with Nanoparticle Tracking Analysis (NTA) using a Malvern 
Nanosight NS300, to give a ratio of 7.5x1011 particles/mg of protein. After the overnight reaction, 
the particles were washed 3 times with PBS as previously described. 
3.2.7 Cell Culture 
Ren–WT cells were cultured in Ren-WT media (RPMI 1640 supplemented with 10% (v/v) 
fetal bovine serum (FBS) and 1% (v/v) antibiotic antimycotic solution (100X)). Ren-mICAM cells 
were cultured with Ren-WT media with extra G418 (Geneticin) at a final concentration of 200 μg 
ml-1.  
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3.2.8 Protection of Endothelial Cells from ROS by Targeted Catalase SPNPs 
Ren-WT and Ren-mICAM cells were trypsinized to single cells and then plated to 96-well 
plates at a density of 35,000 cells/ well.  Cells were cultured overnight to reach confluency. YN1 
and IgG Catalase SPNPs were diluted in Ren-WT media to their final concentrations and incubated 
for 30 min at 37 °C. Then cells were subsequently washed 3 times with Ren-WT media to remove 
unbounded SPNPs. A H2O2 stock (8.8 M) was diluted in Ren-WT media to reach a final 
concentration of 4 mM. Cells were then incubated with 4 mM H2O2 solution at 37 °C cell culture 
incubator for 5 hr. Cell death was assessed based on the levels of lactate dehydrogenase (LDH) 
released to the culture media. LDH levels were measured using Pierce LDH Cytotoxicity Assay 
Kit (Thermo scientific, # 88953), following manufacturer instructions.  
3.2.9 Confocal Microscopy and Cell Staining 
REN cells were seeded in an 8-well chamber slide at a concentration of 100k cells per well 
and allowed to attach overnight. Catalase-loaded SPNPs were then dispersed in cell media to a 
final concentration of 10 μg/ml. Cells were treated for 30 minutes with 200 μL of particle solution, 
and then thoroughly washed with PBS. The cells were then fixed with 4% paraformaldehyde for 
10 minutes and washed with PBS. Cells were permeabilized with Triton-X100, washed and 
blocked with PBS+ 1% BSA, and stained with Alexa-488 Phalloidin, along with a primary Rat 
YN1 antibody, and a Secondary Goat anti-Rat Alexa-555 Conjugate. The cells were finally 
washed, air dried, mounted with a glass cover slip using ProLong Diamond Antifade Mountant 
with DAPI, and allowed to cure for 24 hr prior to imaging. Micrographs were obtained using a 
Nikon A1 inverted confocal microscope with a 60X water immersion objective. Images were 
acquired with excitation at 401 nm, 488 nm, 555 nm, and 641 nm to image the nuclei, actin fibers, 
ICAM, and SPNPs, respectively. NIS-Elements and ImageJ software was used for image 
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acquisition and processing. Images were false colored and digitally treated identically between 
groups to help accentuate differences. 
 Results and Discussion 
3.3.1 Electrohydrodynamic Jetting of Enzyme Loaded SPNPs 
 
Figure 3.1 (A) Schematic of the preparation of Enzyme Loaded Synthetic Protein Nanoparticles 
(SPNPs) made using Electrohydrodynamic (EHD) co-jetting. (B) Particles made using EHD co-
jetting immediately after formation, imaged using Scanning Electron Microscopy. Particles are 
formed and then (C) crosslinked using vapor phase glutaraldehyde as a macromer. (D) 
Nanoparticle size distributions are measured using dynamic light scattering. 
Electrohydrodynamic (EHD) co-jetting was used to synthesize Synthetic Protein 
Nanoparticles (SPNPs) loaded with enzymes. Traditional EHD co-jetting has relied on solvent 
evaporation to solidify the resulting structures, but in EHD co-jetting of proteins, the resulting dry 
protein nanoparticles are unmodified and dissolve in aqueous conditions. SPNPs are thus made by 
modifying EHD co-jetting in a way inspired by reactive extrusion techniques common in chemical 
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engineering, by treating the particles with a crosslinking macromer during or immediately after 
the jetting process. Previous work with Human Serum Albumin SPNPs used short N-
Hydroxylsuccinimide Polyethylene Glycol (NHS-PEG) chains as the macromer component in the 
particles, which react with the Lys residues in proteins to hold the proteins together in the 
SPNPs.169 In preliminary studies that first explored the behavior of SPNPs loaded with enzymes, 
it was found that enzymatic SPNPs made with NHS-PEG lost most of their activity (<0.5% 
residual activity compared to equivalent amounts of free enzyme, data not shown). Circular 
Dichroism (CD) spectroscopy was used to investigate whether the secondary structure of the 
enzymes, which is vital to enzymatic function, was affected by the jetting process. It was found 
that the CD signal of native vs jetted enzyme had been changed, but not as significantly as full 
enzymatic denaturation (Figure 3.2). Due to this, our hypothesis became that the enzymes lost 
their activity due to the seven days at 37 °C required for the NHS-PEG reaction to result in stable 
SPNPs. 
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Figure 3.2 Analysis of jetted enzymes using Circular Dichroism (CD) Spectroscopy. (A) Catalase 
(CAT) was jetted and immediately hydrated without VPGA treatment, and measured using CD 
spectroscopy, alongside native and heat-denatured CAT. (B) CD spectra were then analyzed for 
secondary structure contents using K2d, a neural network method. 
As an alternative, we sought to use glutaraldehyde (GA) as a macromer. Vapor-phase 
glutaraldehyde (VPGA) treatment, a common method used in crosslinking protein-based 
electrospun non-woven fiber scaffolds, was used to introduce GA to the particles. Particles were 
jetted using a solution of 10% (w/w) protein in 90:10 H2O:EtOH (Figure 3.1A). The particles, 
when observed under scanning electron microscopy (SEM), were spherical and smooth, and had a 
relatively broad size distribution (Figure 3.1B), with an average diameter of 113±47 nm (Figure 
3.3). The particles were then placed in a sealed container containing a 20% (v/v) aqueous solution 
of GA in a reservoir (Figure 3.1C). GA reacts with a various of amino acid residues in proteins, 
but mainly with tertiary amines, such as those in Lys residues.164 The macromer acts to hold the 
proteins together as a crosslinker, making them stable in aqueous environments. 
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Figure 3.3 Particle size distribution of SPNPs prior to hydration. To determine size distribution, 
six different SEM micrographs (444 individual particles) were analyzed in MATLAB using the 
function imfindcircle(), and the resulting diameters converted to a frequency histogram 
After VPGA treatment, the particles were immediately collected using a wet collection 
method, where they were scraped off the surface using a plastic razor and a PBS solution with 100 
mM glycine, which reacts with any unreacted aldehydes. This quenching step is commonly used 
to remove any residual reactivity from GA, removing its cytotoxicity.191,192 The particles were then 
size separated to narrow their size distribution using a previously developed serial centrifugation 
technique, where the particles went through a series of sonication, centrifugation, and decanting 
steps at increasing times and speeds, until the desired particle sizes were acquired.193 After the 
particles were isolated, the particles were measured using dynamic light scattering (DLS), and the 
particles were found to have a narrow size distribution, with a z-average of 217 nm and PDI of 
0.156 (Figure 3.1D), and have a volume swelling ratio of 7.09 (hydrated particle volume/ dry 
particle volume). 
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3.3.2 Tuning of Enzyme Activity by Loading 
To study how enzyme activity would be maintained when particles were made using EHD 
co-jetting, two commonly used enzymes were selected. Catalase (CAT), an enzyme notable for its 
strong antioxidative ability, was selected as an example of an enzyme primed for therapeutics.194 
CAT exists in nearly all types of tissues and protects cells from reactive oxygen species (ROS) by 
rapidly catalyzing the degradation of hydrogen peroxide to water and oxygen (eqn. 2).195 
2 H2O
Catalase
O2+2 H2O2     [2] 
While ROS participate in numerous physiologic processes, excessive production during 
acute infection, traumatic injury, hemolysis, ischemia, and reperfusion, among other 
pathophysiologic states can impair critical endothelial functions and result in secondary 
thrombosis, edema, and dysregulation of the innate immune system. ROS damage is manifested 
by a variety of signs, among them the exposure of various adhesion molecules such as VCAM-1 
and ICAM.196 
Glucose oxidase (GOX) was selected as an enzyme that is already in use in various 
industries. GOX is naturally produced by certain species of fungi and insects, and catalyzes the 
oxidation of β-D-glucose to D-glucono-δ-lactone and hydrogen peroxide (eqn. 3).197 
Glucose 
Oxidase
O2 ß-D-Glucose D-glucono-δ-lactone+ + H2O2   [3] 
In nature, GOX acts as an anti-bacterial agent by producing hydrogen peroxide, but is now 
widely used in many  sectors of society, such as the food industry, dairy production, preservatives, 
and in glucose meters.197 
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Figure 3.4 The mass of proteins that are loaded during synthesis are similar to the resulting mass 
in the particles. Mixtures of proteins at various mass ratios, either Human Serum Albumin (HSA) 
and Catalase (CAT) or HSA and Glucose Oxidase (GOX), were made, and then either used as is 
(control) , or jetted and collected (Jetted). (A-B) The samples were then analyzed using SDS-
PAGE gel electrophoresis. The lanes are as follows: L: Ladder, 1: HSA, 2: Enz, 3: Control, 
Enz:HSA-1:99 , 4: Control, Enz:HSA -10:90, 5: Control, Enz:HSA -50:50, 6: Jetted, Enz:HSA -
1:99 , 7: Jetted, Enz:HSA -10:90, 8: Jetted, Enz:HSA -50:50, where Enz is CAT for (A) and GOX 
for (B). (C)The SDS-PAGE was the analyzed using ImageJ, where the intensity ratio between the 
enzyme band and HSA band for each lane was calculated, and then a ratio calculated between the 
control ratio and the jetted ratio, termed the composition retention index. Values close to 1 are 
defined as the control and jetted samples being similar to each other. All tested ratios were within 
the range of 1. 
The activity of each of the above enzymes was studied by modulating the ratio of each 
enzyme and a carrier protein, HSA, on a weight by weight basis. The protein ratio in the particles 
was confirmed by collecting the particles prior to crosslinking and checking their relative 
intensities by running the collected proteins on an SDS-PAGE gel stained with Coomassie Blue 
(Figure 3.4). SPNPs at a variety of enzyme ratios were synthesized and assayed. The particle 
masses were normalized to maintain the amount of enzyme loaded in the reaction solutions. It was 
found that in both GOX and CAT SPNPs, the retained activity of the enzymes in the particles 
decreased as more enzyme was loaded into the particles going from 84.8±6.4% to 31.3+0.3 % 
activity retention for CAT and 55.9±0.9% to 22.0+0.9% for GOX when they were loaded at a 5:95 
Enzyme:HSA ratio compared to a 50:50 ratio (Figure 3.5A). This effect was to be expected, as it 
is generally accepted that when enzymes are immobilized, numerous different factors, such as 
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steric hinderance between enzymes and diffusion limitations, can result in decreased activity 
retentions.176,198 A brief geometric analysis, described in Appendix A, shows how both enzymes 
could quite easily be diffusion limited in their SPNP form, though to date no studies have been 
performed testing this hypothesis. 
 
Figure 3.5 Effect of loading ratio and glutaraldehyde treatment time on enzyme activity and 
particle morphology. (a) The retained activity of enzyme loaded SPNPs is dependent on the 
loading ratio of enzyme to carrier protein. (b) Effects of vapor phase glutaraldehyde treatment 
time. When reacted for different amounts of time, both (b) the retained activities and (c) 
morphologies of the resulting particles are affected. 
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3.3.3 Tuning of Enzyme Activity by GA Treatment Time 
To study how the VPGA treatment time would affect the retained activities of the enzymes, 
particles were treated with GA for various times, ranging from 30 minutes to 24 hours, and then 
collected and size separated. It was observed that particles fused together and lost much of their 
spherical morphology as they were treated for longer time periods (Figure 3.5C). However, in 
terms of activity retention, the two enzymes gave very different results. CAT SPNPs loaded at a 
50:50 ratio had decreasing retained activity with longer treatment, going from 31.3±0.3% at a 30-
minute treatment time to 22.0±0.9% for a 24-hour treatment time. For GOX SPNPs, not only was 
the opposite trend observed, but the unexpected result of enhanced activity was observed. As 
treatment time of GOX particles loaded at a 10:90 ratio increased from 30 minutes to 24 hours, the 
retained activity of the particles increased from 53.8±0.3% to 276.8±12.0% (Figure 3.5B).  
The increase of activity as the GOX SPNPs were treated for longer periods of time with 
glutaraldehyde was surprising, but enzymes having increased activity after immobilization in 
different conditions has previously been reported in multiple studies,199–202 and is theorized to 
occur for a variety of situation specific reasons, ranging from increased diffusion of substrate 
(substrate sponge effect), immobilization resulting in enzyme conformations with higher reaction 
rates, to the immobilization of the enzyme leading to advantageous thermodynamic reaction 
conditions.203 The reason for the discrepancy between the two enzymes, or the increased activity 
observed as a function of VPGA treatment time may be due to the difference in size and complexity 
of the two enzymes, as CAT is an a 250kDa tetrameric complex, with each subunit containing an 
iron, while GOX is a smaller 160 kDa dimer and thus would be less impacted, and possibly even 
stabilized, by sterics.  
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 Still, there could be several potential concerns with this study. If we were measuring 
enzyme activity in a non-linear region, that may explain the results. Also, the assay used to measure 
the GOX does not directly measure GOX activity, but rather a secondary cascade reaction made 
by Horseradish Peroxidase (HRP), which uses the H2O2 produced by GOX to oxidize a detector 
molecule, resulting a measurable change in A570nm. This reaction has a linear region, where A570nm 
increases in a linear fashion, and a subsequent non-linear region where the absorbance decreases. 
If a sample of measured GOX has activity over a certain threshold, it might seem like the enzyme 
is less active than it actually is, if the A570nm is measured in endpoint mode (at the start of the 
reaction and then after a set time), as absorbance may quickly increase, and then decrease once the 
reaction enters the non-linear phase. We are sure that this did not happen, as the reaction was 
followed in kinetic mode, and all measurements used were from the linear region of the reactions.  
 To avoid false activity measurements due to variations in the assay, we only used kits from 
a single production batch. Additionally, the SPNPs that were treated for 30 minutes, which were 
used in subsequent experiments, gave very consistent measurements over a 6-month period, using 
various different kits, across different batches of particles, and in different experiments. 
Additionally, scattering of the nanoparticles themselves might interfere with the measurements, 
but when controls using SPNPs containing only HSA were measured, there was no signal at A570nm. 
These results were confirmed for particle concentrations ranging over five orders of magnitude.  
 Last, incorrect particle concentrations could account for the unexpected results. The 
concentrations of the SPNPs were measured using a BCA assay, which is a protein assay that 
measures a color change that is dependent on the concentration of proteins in a particular solution. 
As the activity assays are highly dependent on accurate measurements of SPNP concentration, if 
the glutaraldehyde treatment time affects the readings of the BCA assay, it may lead to higher 
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readings. However, glutaraldehyde does not change the peptide backbone in proteins, and thus 
there is no reason to think that the protein modifications caused by the aldehyde reactions would 
change the BCA results. In addition, if there was an effect coming from incorrect mass 
measurements, we would have observed noticeable discrepancies between the yields of particles 
made with different treatment times. The particles measured were always from a single large batch 
of jetted particles that were then randomly split and treated for different time periods. With this in 
mind, no differences in yields were observed. 
An additional experiment that may further elucidate the reasons behind the observed trends 
may be to measure GOX activity using a direct measurement of the enzyme products, as was done 
with CAT. These would involve either measuring oxygen consumption in the reaction by 
measuring pressure changes or measuring the produced D-glucono-δ-lactone by titration, as the 
molecule is acidic. By simplifying the measurements by removing the secondary enzyme reaction, 
it might explain the observed results. 
3.3.4 Activity Retention of SPNPs In Different Temperature Conditions and Over Time 
Key to medical applications is how therapeutics maintain their activities not just under 
physiological conditions, but also in pathological conditions and during long term storage. To 
investigate these factors, particle activity was found to be consistent over a 2 week period for 
SPNPs stored at room temperature or at 4 °C. Particles were also incubated for various amounts 
of time at 40 °C, which is representative of the temperature of a patient with a high fever. It was 
found that the particles maintained 82±9% and 78±2% of their initial activities after being in 40 
°C for 20 minutes, for CAT and GOX SPNPs respectively. CAT SPNPs were able to maintain 
their activity much better than free CAT, which only maintained 47±0.2% of its initial activity. 
GOX, on the other hand, behaved differently, as the free enzyme lost none of its initial activity. 
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This was to be expected, as the working temperatures of GOX are both higher and broader than 
CAT, although why the activity of GOX in particle form dropped remains to be explained. (Figure 
3.6). 
 
Figure 3.6 Enzyme loaded SPNP Activity Retention. (A) CAT and (B) GOX SPNPs and their free 
enzyme controls were exposed to 40 °C for varying amounts of time.  
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3.3.5 Using SPNPs to Protect Cells from Oxidative Damage 
 
Figure 3.7 CAT SPNPs were Antibody (Ab) modified. (A) CAT SPNPs were surface modified 
by first reacting the proteins’ surface amine groups with NHS-N3, and subsequently reacting the 
resulting N3 with DBCO modified Abs. (B) There was a measured size increase between the initial 
CAT SPNPs and the Ab-modified CAT SPNPs, using DLS.  
As a potential use case for enzymatic SPNPs in medicine, we next sought to show how 
CAT SPNPs could be used to target endothelial cells and protect them from ROS damage. CAT 
SPNPs made using a 50:50 CAT:HSA ratio were synthesized as previously described using a 30-
minute VPGA time, and subsequently surface modified using two sequential reactions. First 
azidobutyric acid NHS ester was incubated with the particles overnight at 4 °C to functionalize the 
SPNP surfaces with azides. The particles were then incubated overnight at 4 °C with antibodies 
functionalized with dibenzocyclooctyne (DBCO) to perform a copper-free click reaction with the 
azides on the particle surface. This reaction resulted in an increase of z-average of around 30 nm 
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from the unmodified CAT SPNPs to the antibody modified CAT SPNPs (Figure 3.7), and a very 
small decrease in zeta potential of 0.3 mV, measured using electrophoretic light scattering (going 
from -8.3 mV to -8.6 mV). These size and zeta potential differences were consistently seen when 
particles were modified with the various antibodies used. 
 
Figure 3.8 Binding of Antibody targeted enzyme loaded SPNP. Catalase loaded SPNPs were 
surface modified with anti-ICAM antibodies and given to a co-culture of ICAM expressing 
(ICAM+)/Wild-Type (WT) REN cells, and loaded with BSA-Alexa-647 to allow for fluorescent 
visualization. After a 30-minute incubation period, the cells were washed and stained with DAPI 
to cell nuclei (blue), Alexa 488 Phalloidin to actin (green), and an anti-ICAM antibody with an 
Alexa-555 secondary stain (red). 
The selective targeting and protective potential of antibody targeted CAT SPNPs was first 
studied in a model in vitro system. REN cells, a human mesothelioma cell line, were genetically 
modified to express ICAM on their surface as previously reported.204 To confirm high specificity 
of the antibodies, confocal microscopy was used on a co-culture of ICAM/WT REN cells treated 
with either non-specific IgG antibodies, or anti-ICAM YN1 rat antibodies, which were additionally 
loaded with fluorescent Bovine Serum Albumin. High particle uptake was only observed in cells 
staining positive for ICAM expression (Figure 3.8). Protective potential was then tested by 
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incubation with YN1 or IgG CAT SPNPs (Figure 3.9). After a 30-minute incubation period, the 
cells were washed and treated with 10 mM H2O2. The viability of the cells after the treatment was 
then measured, and it was found that the YN1 targeted nanoparticles were able to specifically 
protect up about 80% of ICAM-expressing cells, while non-specific controls provided no 
significant effect (Figure 3.10).  
Figure 3.9 Cells were treated with various antibody modified CAT SPNPs to analyze them for 
their potential to protect cells from ROS. 
 
 
65 
 
Figure 3.10 Targeted enzyme loaded SPNPs protect cells from ROS damage. ICAM expressing 
or WT REN cells were treated with Ab or IgG CAT SPNPs and exposed to 10 mM H2O2. Viability 
was then determined by measuring LDH released into the cell media as a marker of cell death, as 
compared to untreated cells. 
Protection of cells in an in vitro inflammatory disease model was then investigated to better 
mimic clinical application. HUVEC cells were first treated with TNF-α to mimic an inflammatory 
pathology. TNF-α was used to induce expression of ICAM on the surface of the cells.205 CAT 
SPNPs modified with R6.5, a human anti-ICAM, or IgG antibodies were then given to the cells. 
The cells were treated with H2O2 as previously described, and it was found that the particles were 
able to protect the 90% of cells, while non-specific and carrier controls had less effect, 70% and 
35% protection, respectively (Figure 3.11). The ability of the SPNPs to specifically protect 
targeted cells and the retention of the enzymatic therapeutic activity shows the potential for these 
particles to be used as enzyme delivery vehicles. 
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Figure 3.11 Protection of human primary cells in an inflammatory disease model. HUVECs were 
treated with TNF-α to mimic an inflammatory environment. Cells were then treated with Ab, IgG, 
or unmodified CAT SPNPs, along with an Ab carrier control for 30 minutes and then challenged 
with 10 mM H2O2. Cell viability was assayed by measuring LDH released. 
3.3.6 Bicompartmental Enzyme Loaded SPNPs 
 
Figure 3.12 Enzymatic cascade model of GOX CAT and HRP. The two-step system has HRP 
consume the H2O2 produced by GOX, producing a color change in an indicator molecule. H2O2 
can be scavenged by CAT when present, reducing the color change in the reaction. 
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There is strong interest in the biotechnology space for improving the efficiencies of 
enzymatic chemical reactions. One of the proposed methods to improve reactions is through the 
use of compartmentalized enzymes.206 GOX and CAT are commonly used to study cascade 
enzymatic reactions, as the hydrogen peroxide produced by GOX is the substrate for CAT. Thus, 
the same assay used to measure GOX previously was adapted to measure the synergy between the 
enzymes when loaded in SPNPs (Figure 3.12).  
 
Figure 3.13 One and two compartment SPNPs have similar size distributions. Particles made using 
EHD co-jetting have similar size distributions, whether they are made with one or two 
compartments, as measured using DLS. 
To showcase how synergistic enzymes could be loaded in anisotropic (bicompartmental) 
versions of the particles, SPNPs loaded with GOX in one compartment, and CAT in the other 
(GOX:CAT SPNPs) were synthesized using a parallel capillary system (Figure 3.14A).115,122 Once 
size segregated, the anisotropic SPNPs had a similar size distribution as single compartment 
particles (Figure 3.13). The activity of GOX SPNPs and GOX:CAT SPNPs with the same amount 
of active GOX was measured, and there was a clear decrease in the change of absorbance when 
CAT was added (Figure 3.14B). This is the result that would be expected in a when a particle 
system containing GOX and CAT is present. The assay normally functions by having HRP use the 
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H2O2 produced by GOX to oxidize AbRed, a colorimetric detector molecule. When a portion of 
the H2O2 is consumed by CAT, a decreased amount of absorbance is observed, when compared to 
a particle system only containing GOX. These proof of concept results show the ability to load 
two enzymes in two compartment SPNPs, and further studies are planned to study possible 
synergistic effects of compartmentalizing enzymes in SPNPs. 
 
Figure 3.14 Two compartment enzymatic cascade SPNPs. (A) Two compartment SPNPs were 
synthesized using EHD co-jetting, resulting in particles with GOX in one compartment, and CAT 
in the other. (B) When placed in a reaction buffer containing HRP, Glucose, and a colorimetric 
indicator, the H2O2 produced by GOX was partially scavenged by CAT in the two compartment 
particles, leading to a reduced color change compared to single enzyme with equivalent amounts 
of GOX. 
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 Summary 
In this study, we report the development of a method to synthesize enzyme-loaded Synthetic 
Protein Nanoparticles (SPNPs). We show how two different proof-of-concept enzymes can be 
loaded into the particles at a variety of loading ratios, and how by changing the synthesis 
conditions, we can modulate the retained activities of the loaded enzymes. It was also shown how 
enzymatic particles could be targeted to specific cells using antibodies, and a small study was 
conducted to show the effectiveness of Catalase loaded SPNPs in protecting endothelial cells from 
reactive oxygen species damage. Notably, we were also able to show how two compartment 
particles, each loaded with a different enzyme, were able to conduct a cascade enzymatic reaction. 
While these experiments were all designed as proof-of-concept studies of enzyme loaded SPNPs, 
they all show the potential of  these particles for a variety of potential applications in medicine. 
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Chapter 4 
Characterization of Synthetic Protein Nanoparticles with Electrokinetic Microfluidics 
 
Part of the material for this chapter has been adapted with modifications from the following 
publication: 
 
1. D. F. Quevedo, C. J. Lentz, A. Coll de Peña, Y. Hernandez, N. Habibi, R. Miki, J. Lahann, 
and B. H. Lapizco-Encinas “Electrokinetic Characterization of Anisotropic Synthetic 
Protein Nanoparticles” Beilstein Journal of Nanotechnology, Under Review, 2020. 
 
 Background and Motivation 
 Over the past thirty years, nanoparticles have been developed for a broad variety of 
scientific applications, ranging from medical imaging to drug delivery and enzyme immobilization 
to industrial processes.207,208 An emerging sector in nanotechnology has been the development of 
nanoparticles composed primarily of proteins.209 Proteins have multiple desirable characteristics 
for use as the main material components of nanoparticles: they are biodegradable, naturally 
involved in biological molecule targeting, and are “smart” materials that can respond to various 
environmental cues such as pH, temperature, or target binding.210 Protein nanoparticles (PNPs) 
have proven useful for the loading of active therapeutic enzymes and show promise as 
vaccines.91,139 Using protein engineering techniques, there has also been significant advances in 
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self-assembled PNPs.211,212 PNPs have successfully reached the clinic, with nab-paclitaxel 
(Abraxane®), a PNP made of Human Serum Albumin, being used for the treatment of metastatic 
breast cancer, non-small cell lung cancer, and pancreatic adenocarcinomas.213 While current 
technologies allow for the synthesis of smart PNPs that release their active enzymatic payloads in 
oxidative environments,91 a next step in  further developing smart protein nanoparticle 
technologies is to develop a scalable method for producing sub-compartments within particles. By 
localizing proteins at the nanoscale, PNPs could have further applications in controlled release and 
delivery of therapeutics, theragnostics, and enzymatic cascades.214 
 Although previously developed methods to produce PNPs, such as coacervation,139 self-
assembly,215 and pressure driven techniques,216 allow for intraparticle spatial control of material 
composition through layer by layer techniques, no previous synthetic schemes are able to 
synthesize anisotropic protein nanoparticles with distinct hemispheres. To address this unmet need, 
we have adapted EHD co-jetting techniques, previously established by the Lahann lab, to create 
single-compartment and multicompartmental (i.e. anisotropic) synthetic protein nanoparticles 
(SPNPs and ASPNPs) that can be easily made from a variety of proteins.119 A recent publication 
showcases how this versatile technique can be used to create particles that have significant 
potential as therapeutics, in particular their ability to treat glioblastoma.169 To transition the 
promising results of these particles into the clinic, high-throughput purification and 
characterization techniques that are specific for anisotropic particles need to be developed. 
 In the last decade, the area of microfluidics, the field of science that studies the 
manipulation of minute volumes of fluids (microliters to picoliters),217 has experienced a 
significant growth in bioanalytical applications.217,218 Electrokinetics (EK) and electric-field 
driven processes are suitable for a wide range of applications due to their simplicity and robustness. 
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An applied electric potential can be used for both manipulating a bioparticle and its surrounding 
liquid, as electroosmotic (EO) flow can allow for “on the fly” dynamic flow re-direction within a 
device for further collection and analysis.219 Both AC and DC electric potentials can be used to 
exploit differences in specific bioparticle properties, such as electrical charge, size, shape and 
polarizability.220,221 An important fraction of miniaturized EK devices employ a combination of 
electrophoresis (EP), dielectrophoresis (DEP) and EO flow effects,222 allowing for additional 
parameters to fine-tune a separation process. Particle characterization and manipulation with EK 
techniques offer the potential for developing novel separation schemes for the sorting and 
enrichment of bioparticles of interest. Furthermore, it has been shown that nonlinear EK effects, 
such as EP of the second kind,223,224 are very effective mechanisms for controlling particle 
migration within microdevices. An advantageous strategy for enhancing nonlinear EK effects on 
particles is to use insulator-based EK devices, where insulating structures distort the electric field 
distribution generating regions within the device of higher electric field strength.225 These are 
simple devices, usually made from a single substrate, making microscale EK methods promising 
for high-throughput purification applications. Furthermore, a recent development was the 
universal design parameter, the electrokinetic equilibrium condition (𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸) reported by Coll De 
Peña et al.,225 that only depends on physical particle characteristics and can optimize the design of 
EK separations. 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸, as a unique particle-dependent parameter, can predict the required particle 
trapping voltages in any insulator-based EK device.  
 Microscale EK can be used to manipulate particles across size scales,226 from proteins,227–
229 to viruses, 230 to cells,231,232 to parasites.233 Traditionally, these type of microscale studies were 
labeled as DEP methods, although more recently it has been reported that the major phenomena 
controlling particles in these systems was EP of the second kind.225,234 DEP for the manipulation 
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of proteins was first reported in 1994 by Washizu et al.235 via dielectrophoresis chromatography. 
Since then, other studies  have demonstrated the potential of DEP for the manipulation of 
macromolecules.236–238 However, microscale EK techniques for proteins are still developing. The 
Ros research group has reported both the trapping and streaming of protein particles employing 
devices with micro and nano insulating posts228,239–241 as well as the sorting of protein nanocrystals 
with streaming insulator-based DEP.242–244 The Swami and Chou groups have studied the 
enrichment of protein particles under conditions of high conductivity media employing devices 
with nano-gaps and reported both positive DEP and negative DEP.227,245–247 Other studies have 
employed triangular insulating posts with nanogaps,248 cylindrical insulating structures to enrich 
BSA particles,249 or diamond-shaped post to separate PEGylated ribonuclease A from non-
PEGylated molecules.250 
 The potential advantages of using microscale EK techniques with insulating structures 
include ease of manufacture and high-throughput parallel processing, making EK methods a key 
candidate for use in purifying SPNPs for clinical applications. Besides exploiting size differences, 
microscale EK techniques can also exploit differences in both electrical charge and dielectric 
properties, making them uniquely suited to process and purify SPNPs. EK techniques could also 
be used to differentiate between SPNPs and ASPNPs, since the anisotropic particles, whose polar 
ends have different properties, should have different behavior in the microdevices compared to 
their single compartment counterparts. In this work, we present the characterization of 
electrohydrodynamic (EHD) co-jetting synthesized SPNPs in a custom-built system, as well as the 
application of EK techniques to characterize SPNPs made of Bovine Serum Albumin (BSA) and 
Lysozyme. Two types of particles were synthesized: particles that were homogenous blends of 
proteins, and anisotropic particles. A total of eight distinct types of SPNPs were electrokinetically 
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characterized. The results illustrated that particle composition strongly influences the voltage at 
which SPNPs will trap in an insulator-based EK device. Moreover, homogeneous particles with a 
higher content of BSA showed lower trapping voltages. The results also indicated that particle 
anisotropy plays an important role in determining trapping voltage, as 50:50 homogeneous SPNPs 
required a much lower trapping voltage than 50:50 anisotropic SPNPs. All eight particle samples 
were characterized in terms of their electrophoretic mobilities, linear and nonlinear, and in terms 
of their 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸. These measurements expand the approach of using 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 to characterize 
nanoparticles and allow for the accurate prediction of SPNPs behavior in any EK device. The 
results obtained here shed light on the great potential of the use of insulator-based EK devices for 
the analysis and purification of protein nanoparticles.  
 Methods 
4.2.1 Nanoparticle Synthesis, Purification and Characterization 
Particles were synthesized using the EHD co-jetting method. The protein(s) of interest and 
2kDa NHS-PEG-NHS copolymer were dissolved at 10% w/v and 1% w/v, respectively, in a 90:10 
(ultra-pure H2O:EtOH) solution. They were subsequently flown through a syringe at a rate of 0.1 
mL/hr, and a voltage was applied between the needle and collecting surface to produce a Taylor 
cone. The voltage caused the droplet to be pulled towards the collecting substrate and subsequently 
break up into the nanometer sized spheres. In mid-flight, the solvents rapidly evaporate to form 
the solid nanoparticles. For bicompartmental particles, the needles were placed in a parallel 
configuration to create a laminar flow at their ends, as described previously, and all other 
conditions were identical. For the polycondensation reaction, where the NHS groups in the PEG 
copolymer react with lysine groups in the proteins, the nanoparticles were placed in a dry 37 °C 
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oven for 7 days. All SPNP synthesis reagents were purchased from Sigma Aldrich and Fisher 
Scientific. 
After polycondensation, the particles were collected by scraping them off the collecting 
surface using a solution of Ultrapure H2O + 0.01% Tween 20. The collected solution was then 
sonicated on ice, run through a Falcon 40 μm cell filter (Fisher Scientific), and then centrifuged at 
3,200 RCF for 5 minutes to remove large particles. The resulting supernatant was then centrifuged 
at 21,130 RCF for 40 minutes to collect the desired particles. 
Particles, in their dry state, were imaged using SEM to analyze their shape. To determine 
their hydrodynamic size distribution after being hydrated, the particles were suspended in 
Ultrapure H2O + 0.01% Tween 20, sonicated on ice, and measured with dynamic light scattering 
(Malvern ZSP ZEN-5600), using standard settings. An average of at least three measurements are 
reported. Particle zeta potential was measured on the same instrument using a disposable folded 
capillary cell (DTS1070, Malvern) and using standard settings. Protein concentration was 
measured using a Pierce BCA assay using a BSA standard for the standard curve. Particle 
fluorescence was confirmed using a Leica DMi8 inverted microscope (Wetzlar, Germany) that 
was paired with a Leica DFC7000 T camera and the software LASX provided by the manufacturer. 
4.2.2 Microdevice Fabrication 
Microchannels with oval-shaped insulating posts (Figure 4.1) were made from 
polydimethylsiloxane (PDMS) employing standard soft lithography techniques. To create a 
device, PDMS (Dow Corning, Midland, MI) was cast onto a negative replica mold made with a 
silicon wafer (Silicon Inc., Boise, ID) and SU-8 3050 photoresist (MicroChem, Newton MA). 
After curing, the PDMS slab was sealed with a PDMS-coated glass wafer using a corona wand 
(Electro Technic Products, Chicago, IL), creating microchannels where all internal surfaces are 
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PDMS and have same wall zeta potential (𝜁𝜁𝑊𝑊), ensuring consistent EOF. The microchannels were 
10.16 mm long, 0.88 mm wide, 40 μm deep and contained one inlet and one outlet liquid reservoir. 
 
Figure 4.1 Schematic representation, with dimensions, of the iDEP device used in this study 
depicting the dimensions of the channels and the insulating posts. 
4.2.3 Microfluidics Experimentation  
Before placement in the microfluidic device, fully characterized SPNPs were pelleted by 
centrifugation at 21,130 RCF for 40 minutes and suspended at 2.5 mg/mL in Ultrapure H2O + 
0.01% Tween 20. Particles were then diluted to 250 μg/mL in the same suspending media used to 
fill the device (K2HPO4 buffer with a pH of 6.16 and a conductivity of 21.3 μS/cm, supplemented 
with 0.05% Tween 20) and subsequently sonicated to break up particle aggregates. A sample of 
suspended SPNPs (1-5 μL) was injected into a device before electrodes were inserted and the 
pressure was equalized. In order to determine the trapping voltage of one particular type of SPNP, 
a range of increasing voltages were tried on a single sample until particle trapping in the form of 
77 
bands was observed, such as the bands seen in Figure 4.3c and Figure 4.3d. Once this approximate 
trapping voltage was found, a new channel and sample was used to test voltages at and below the 
approximate trapping voltage. With the new sample, each time a new voltage was applied, the 
system was returned to neutral pressure, and voltages were decreased by 100 V increments until a 
smooth trapping band was no longer observed. 
 Results and Discussion 
4.3.1 Synthetic Protein Nanoparticle Synthesis and Characterization 
SPNPs were synthesized using a modification of the well-established technique of EHD 
co-jetting.115,122,251 Generally, SPNP fabrication starts by dissolving a protein of interest and 
macromer of choice into a co-solvent system of water and an organic solvent, such as ethanol or 
ethylene glycol.169 The mixture is then ejected through a small gauge needle toward a collecting 
surface. A high voltage (kV range) is placed between the needle and the collecting surface, which 
leads to the formation of a Taylor cone in the droplet of solution at the end of the needle. At the 
tip of the Taylor cone, the fluid jet breaks and nanoparticles are formed (Figure 4.2A). EHD co-
jetting builds off electrospraying by incorporating a second parallel syringe to create 
multicompartmental, or anisotropic, structures. With the use of varying device designs and 
synthetic parameters, a variety of different particle and fiber architectures can be made.123,252 
Bovine Serum Albumin (BSA) SPNPs were synthesized using EHD co-jetting, with BSA 
as the protein and a macromer composed of poly(ethylene glycol) (PEG, 2 kDa) terminally 
bifunctionalized with N-hydroxylsuccinimide esters (NHS) as the copolymer. The NHS esters 
react with the lysine groups in BSA to polymerize into insoluble SPNPs. The SPNPs were of 
uniform shape when imaged using scanning electron microscopy (SEM). We further analyzed the 
size distribution of the particles using ImageJ software and found that the particles had an average 
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diameter of 299±128 nm (Figure 4.2B). The particles were subsequently collected and suspended 
in buffer, leading to hydration. The average particle diameters had increased to 356±190 nm when 
measured using dynamic light scattering (DLS). The size distributions found by SEM and DLS 
were similar to those previously found with EHD jetting.253 The size difference between the SEM 
and DLS measurements was a result of the particles solvation state, as they swell in water.  
To test the potential of EK microfluidics as a high-throughput SPNP purification technique, 
a way to visualize our particles using fluorescent microscopy was needed. To achieve this, we 
incorporated commercially available Alexa Fluor dyes conjugated to BSA as fluorescent markers 
at 0.8% (w/w) of total protein into the initial electrospraying solution. After the purification steps 
described previously, we were able to clearly observe particles under typical microscopy 
conditions (Figure 4.2C). 
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Figure 4.2 Fabrication process of Synthetic Protein Nanoparticles (SPNPs). (A) Representation of 
the electrohydrodynamic co-jetting process. (B) SEM image demonstrating the morphology of the 
SPNPs as synthesized, (C) Image of SPNPs loaded with BSA-Alexa 488 to make them visible for 
characterization through microscale electrokinetic experimentation. Fluorescence was confirmed 
using a fluorescent microscope. 
4.3.2 Effect of Size Differences and Fluorescent Dyes 
For potential applications in theragnostics where fluorescent markers in the particles could 
be needed, we were interested in first investigating whether the incorporation of different 
fluorescent dyes in our particles would affect the particle behavior in EK microfluidics. Thus, we 
synthesized BSA SPNPs loaded with Alexa Fluor-488 (SPNP-BSA-488) or Alexa Fluor-555 
(SPNP-BSA-555) and explored their behavior in an EK device. The resulting particles were fully 
characterized, and it was found that the SPNP-BSA-488 and SPNP-BSA-555 had hydrodynamic 
diameters of 373±180 nm and 356±190 nm, respectively (Figure 4.3A). The zeta potentials of the 
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SPNPs (𝜁𝜁𝑝𝑝) were also measured in a K2HPO4 buffer, which was the same buffer used in EK 
experiments, using electrophoretic light scattering and found to be -20.0±0.6 mV for the SPNP-
BSA-488 and -17.4±0.6 mV SPNP-BSA-555.  
The EK devices to study these particles were made using microdevice manufacturing 
techniques as previously described. Standard soft lithography techniques were used to cast 
polydimethylsiloxane (PDMS) onto molds, and the resulting microdevices were sealed with 
PDMS-covered glass wafers to ensure all the internal walls had the same zeta potential (𝜁𝜁𝑤𝑤). These 
microchannels were designed to include an inlet and an outlet liquid reservoir where electrodes 
are placed, and an array of PDMS insulating posts located at the center of the channel (Figure 
4.3B). Particles are introduced at the inlet reservoir prior to applying an electric potential. In the 
devices, as the electric potential is applied particles will begin migrating in the device towards 
either the inlet or outlet reservoirs. The particles stop migrating, or “trap”, at a certain voltage due 
to the constrictions between the insulating posts. The voltage at which a particle traps is directly 
related to the properties of the particle (e.g., electrical charge, size, shape, and polarizability); 
therefore, every particle type will trap at a different voltage. These differences in trapping voltage 
can be used to separate and characterize particles. The trapping voltages can also be used to 
estimate the 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸, a parameter that can be used to find the trapping behaviors across any 
microdevice design, for each particle type. These calculations will be covered later in this study. 
SPNP-BSA-488 and SPNP-BSA-555 were both measured in the EK microdevices and both 
particle types were found to trap at the same potential, 500 V (Figure 4.3C and Figure 4.3D). This 
result, suggesting that the presence of the dye does not affect the EK response, has been reported 
in the literature in similar EK microdevices.254 This lack of a difference in trapping voltage even 
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in the presence of different fluorescent dyes shows that the dye molecules themselves have no 
evident effect on the particles’ EK behavior. 
 
Figure 4.3 Results illustrating the effect of the fluorescent dye on dielectrophoretic trapping. (A) 
DLS size distributions of BSA SPNPs labeled with Alexa Fluor-488 (green) and Alexa Fluor-555 
(red). (B) A schematic representation of the EK microfluidic devices used, and how particles trap 
within the devices (insert). (C) Trapping of SPNP-BSA-488 and (D) Trapping of SPNP-BSA-555. 
Both types of SPNPs were trapped at an applied voltage of 500 V, exhibiting very similar trapping 
behavior. Flow direction is from positive to negative (right to left) in images b, c, and d. 
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4.3.3 Electrokinetic Response of SPNPs Composed of Different Proteins 
EK microfluidics could potentially be used to separate SPNPs of two different proteins 
based on size and 𝜁𝜁𝑝𝑝, and thus we next investigated the trapping voltages of SPNPs composed of 
two commonly used model proteins, BSA and Lysozyme. The two proteins have significantly 
different isoelectric points: 11.35 for lysozyme and 5.4 for BSA. This difference in isoelectric 
point implies that the two particles behave differently in an EK device. SPNPs were synthesized 
whose main protein was lysozyme (SPNP-Lys-488) or BSA (SPNP-BSA-488). The particles were 
fully characterized (Table 4.1). SPNP-Lys-488s were of a similar size distribution and 𝜁𝜁𝑝𝑝 as the 
BSA SPNPs, when measured in EK buffer (Figure 4.4). While surprising, considering the different 
isoelectric points, the lack of a difference in 𝜁𝜁𝑝𝑝 was likely due to the buffer used, as when the 
particles were measured in DPBS, they had significantly different 𝜁𝜁𝑝𝑝 of -3.5±0.5 mV and 11.2±0.9 
mV for the SPNP-BSA-488s and SPNP-Lys-488s, respectively. 
 
Figure 4.4 Plot of SPNP size distributions measured with dynamic light scattering. 
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The SPNP-Lys-488s were then analyzed using an EK device as previously described, and 
the particles trapped at 2300 V. This voltage significantly differed from the 500 V obtained for 
SPNP-BSA-488s, suggesting that the two particle types could be easily differentiated using EK 
microfluidics. 
4.3.4 Electrokinetic Response of SPNPs as Function of Particle Composition 
Possible SPNP therapeutics could be made from a mixture of different proteins in a single 
particle, such as a mixture of a carrier protein and an active protein like an enzyme.91 To investigate 
the sensitivity of EK microfluidics to detect differences in blends of two proteins in single particles, 
SPNPs were made that were composed of a variety of ratios of BSA and Lysozyme. The particle 
compositions sizes and 𝜁𝜁𝑝𝑝 are described in Table 4.1. The particles were then analyzed using an 
EK microdevice. Generally, when the amount of Lysozyme in the particles was increased, the 
voltage required to trap the particles increased as well (Figure 4.6). This shows promise for EK 
microfluidics to detect SPNPs that are composed of blends of different proteins. Images depicting 
the trapping of the eight particles samples are included in Figure 4.5. 
 
Figure 4.5 Images depicting the EK trapping of the eight types of SPNPs used in this study 
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Table 4.1 Composition of the eight distinct types of PNPs studied here, listing the percentage 
composition of BSA and Lysozyme as well as their respective hydrodynamic diameters and zeta 
potentials.  
Particle Sample Particle Composition Hydrodynamic Diameter (nm) 𝜻𝜻𝒑𝒑 (mV) 
BSA 100% BSA 356±190 -20.0±0.6 
Lysozyme 100% Lysozyme 277±130 -20.5±2.2 
90:10 blend 90% BSA 10% Lysozyme 367±201 -20.6±1.0 
75:25 blend 75% BSA 25% Lysozyme 302±168 -14.6±0.5 
50:50 blend 50% BSA 50% Lysozyme 360±169 -14.5±0.9 
25:75 blend 25% BSA 75% Lysozyme 304±100 -22.1±1.9 
10:90 blend 10% BSA 90% Lysozyme 266±94 -20.3±1.8 
50:50, bicompartmental 
Compartment 1: 100% 
BSA 
Compartment 2: 100% 
Lysozyme 
322±172 -14.1±2.7 
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Figure 4.6 Experimental results of the trapping voltage of the seven types of SPNPs composed of 
BSA, Lysozyme, or blends of both proteins. The bottom image illustrates how the trapping 
voltages trended as function of the SPNPs composition, where the voltage required to trap the 
particles increased as the amount of Lysozyme increased. Images of trapped SPNPs are included 
in Figure S3. 
4.3.5  Electrokinetic Response of ASPNPs 
A final point of interest was whether EK microfluidics can differentiate particles based not 
only on general composition, but also on local anisotropy. Thus ASPNPs, with one hemisphere 
composed entirely of BSA, and the other of lysozyme, were synthesized. Note that compositionally 
this would be equivalent to the 50-50 particles tested earlier (Figure 4.7A). However, when the 
trapping voltage of the ASPNPs was measured, it was found to be 1500 V, making a 600 V  
difference in trapping voltage between ASPNPs and particles made of a 50:50 w/w ratio of BSA 
and lysozyme (Figure 4.7B). This voltage differential is significantly larger than the possible step 
sizes of EK microfluidics, which are in the range of 23 V to 50 V.225 Although the two particle 
types were identical in material composition, EK microfluidics were able to differentiate the 
subpopulations purely by the distribution of matter within each particle.  
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That this was observed is to be expected, but the specifics behind the physics are yet to be 
explained. An unexplained facet of this is the fact that the bicompartmental particles had a higher 
trapping voltage than its isotropic counterpart. It would make intuitive sense for the anisotropic 
particles to have a lower trapping voltage, as they would have a natural polarity due to their 
material distribution, and thus be easier to polarize, ergo require a lower voltage to trap, but the 
opposite result was observed. It is unknown why this happened, but it might be that the behavior 
of the anisotropic particles is a result of them acting like two particles that are physically attached 
to each other. This hypothesis would require a more in-depth quantitative examination to prove its 
validity that is outside the scope of this work, due to the complex kinetics that occur in 
electrokinetic devises,255 many of which can be calculated, but some more novel effects such as 
non-linear electrokinetic phenomena,256–258 which cannot currently be calculated. Given this, the 
unique trapping voltage of ASPNPs vs protein blend SPNPs is still notable, as it shows the 
potential of ASPNPs to be sorted using EK microfluidics.  
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Figure 4.7 PNP material distribution and trapping voltage characteristics. (A) Schematic 
representation of SPNPs composed of a homogeneous mixture of BSA and Lysozyme, and 
ASPNPs made in a bicompartmental configuration. (B) Illustration of the trapping voltages of the 
two types of SPNPs, which were significantly different between the two types of particles. 
4.3.6 Estimation of Non-Linear Electrokinetic Parameters 
Having obtained the applied voltage necessary to trap each type of SPNP, it was then 
possible to derive the electric field magnitude at which each SPNP type would have zero velocity 
(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸). The previously developed technique225 to calculate particle 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 relies on the fact that 
trapped particles (Figure 4.8A) trap along isoelectric lines (Figure 4.8B). The lowest magnitude 
isoelectric line, the line passing through the midpoint of the constriction, forms a “barrier” which 
only particles with an 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 higher than the electric field magnitude along this line can pass through. 
With this information obtained from experiments, the 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 of each SPNP listed in Table 4.2 was 
calculated by simulating the electric field within a constriction using COMSOL Multiphysics at 
the trapping voltage of each particle.  
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The nonlinear electrophoretic mobility (𝜇𝜇𝐸𝐸𝐸𝐸
(3)) was obtained,259 since both 𝜇𝜇𝐸𝐸𝐸𝐸 and 𝜇𝜇𝐸𝐸𝐸𝐸(1) were 
experimentally obtained a priori, employing particle image velocimetry and current monitoring 
measurements.260 Knowing both the linear and nonlinear EP mobilities is an essential component 
for the design of EK particle separations. 
 
Figure 4.8 (A) Image of trapped Lysozyme SPNPs at 2100 V. (B) Plot of electric field magnitude 
inside post constriction with black isoelectric field lines at an applied voltage of 2100 V. 
Table 4.2 Electrokinetic properties of the eight distinct types of SPNPs studied here. 
Particle Sample 𝑬𝑬𝑬𝑬
(𝟏𝟏) Mobility 
𝝁𝝁𝑬𝑬𝑬𝑬
(𝟏𝟏) (m2V-1s-1) 𝑬𝑬𝑬𝑬(𝟑𝟑) Mobility 𝝁𝝁𝑬𝑬𝑬𝑬(𝟑𝟑) (m4V-3s-1) 𝑬𝑬𝑬𝑬𝑬𝑬𝑬𝑬 (V/m) 
BSA -1.44E-08 -1.15E-18 2.31E+05 
Lysozyme -1.45E-08 -1.37E-19 6.68E+05 
90:10 -1.49E-08 -3.17E-18 1.38E+05 
75:25 -1.04E-08 -1.51E-18 2.08E+05 
50:50 -1.05E-08 -3.78E-19 4.15E+05 
25:75 -1.58E-08 -1.43E-19 6.46E+05 
10:90 -1.43E-08 -1.28E-19 6.92E+05 
Bicompartmental -1.01E-08 -1.37E-19 6.92E+05 
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 Summary 
In summary, we have shown a potential high throughput method to characterize and 
manipulate synthetic protein nanoparticles. We synthesized eight distinct types of SPNPs with a 
variety of different characteristics, ranging from different fluorescent dyes, protein compositions, 
and particle anisotropies (homogenous vs. anisotropic). Particles were tested in EK microfluidic 
devices with oval-shaped insulating posts, illustrating the potential of EK techniques for the rapid 
enrichment and characterization of SPNPs. Notably, the results illustrated that by employing 
insulator-based EK microfluidics, we differentiated between SPNPs by two distinct 
characteristics: protein composition and anisotropy. The electric potential required to 
electrokinetically “trap” and enrich homogenous SPNPs depends on the particle composition, i.e., 
the relative fractions of BSA and Lysozyme. The higher the Lysozyme fraction within the SPNPs, 
the higher the electric potential required. In terms of particle anisotropy, homogenous SPNPs 
required a much lower electric potential to be electrokinetically trapped than ASPNPs separated 
into two hemispheres. Furthermore, a complete EK characterization for all eight SPNPs samples 
was reported, which includes particle zeta potential, two types of electrophoretic mobility and the 
electrokinetic equilibrium condition (𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸).225 This latter parameter is an essential component that 
integrates the main EK phenomena acting on the particles, and has the potential to be used for the 
design and optimization of these systems. The 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 is analogous to an EK signature, that is, this 
value remains constant for a particular particle type in any insulator-based EK system. Differences 
in particle dielectric properties can be exploited for the design of EK-based separation processes. 
These results show the promise for EK microfluidics to be used as a technique for the 
characterization and separation of synthetic protein nanoparticles. .
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Chapter 5 
Toward Medical Applications of EHD Co-jetted Nanoparticles 
 Background and Motivation 
Neuroblastoma is a solid extracranial cancer of the nervous system. It mainly affects 
children under fifteen years old and accounts for 15% of childhood cancer deaths.261 A treatment 
for certain high-risk patients uses iodine-131 meta-iodobenzylguanidine (I-131 MIBG,  
Figure 5.1A). MIBG is a norepinephrine analogue that localizes to adrenergic cells.262 
Neuroblastoma cells overexpress adrenergic transporters, such as the norepinephrine transporter 
(NET), and thus take up MIBG at higher rates than other tissues; because of this, when modified 
with I-131, MIBG is used as radiotherapy.263 I-131 MIBG treatment, as a targeted therapy, avoids 
many of the side effects seen in other cancer treatments and is highly efficacious, but its 
radioactivity causes a need for specialized facilities and harsh conditions for patients.264 MIBG is 
a norepinephrine analogue that localizes to adrenergic cells.262 Neuroblastoma cells overexpress 
adrenergic transporters, such as the norepinephrine transporter (NET), and thus take up MIBG at 
higher rates than other tissues. Because of this, when modified with I-131, MIBG is used as 
radiotherapy.263 I-131 MIBG treatment, as a targeted therapy, avoids many of the side effects seen 
in other cancer treatments and is highly efficacious, but its radioactivity causes a need for 
specialized facilities and harsh conditions for patients.264 
Particles fabricated through EHD co-jetting can be made of a variety of polymers. Work 
done in this chapter was done at the beginning of my studies before the thorough development of 
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Synthetic Protein Nanoparticles (SPNPs), and thus was done using nanoparticles made from 
poly(lactic-co-glycolic acid) (PLGA, 
Figure 5.1C). PLGA is a biodegradable co-polymer that that has been in use in the drug delivery 
field for decades, is a component in a large number of FDA approved therapeutic devices, and so 
was, at the time of this study, a more clinically validated material compared to protein 
nanoparticles.265 Additionally, the synthesis of a number of chemically modifiable PLGA variants 
is well established, which gives more flexibility for surface modifications of NPs vs SPNPs.122 
The azide-alkyne Huisgen cycloaddition, commonly known as a copper catalyzed click reaction, 
is an example of a reaction that can be used with poly(lactic acid-co-2-methoxy-3-oxo-3-(2-
oxopropoxy)propyl pent-4-ynoate) (PLGA-Alkyne) ( 
Figure 5.1D). The side group in PLGA-Alkyne can be reacted in gentle conditions with molecules 
containing azide (N3) groups. By carefully designing reaction schemes, sequences of molecules 
can be added to the surfaces of NPs. 
 
Figure 5.1 A variety of polymers and molecules were used to make NPs for neuroblastoma 
targeting. (A) meta-iodobenzylguanidine (MIBG), (B) meta-acetylenbenzylguanidine (MABG), 
(C) poly(lactic-co-glycolic acid) (PLGA), (D) poly(lactic acid-co-2-methoxy-3-oxo-3-(2-
oxopropoxy)propyl pent-4-ynoate) (PLGA-Alkyne) 
A B 
C D 
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As an alternative to I-131 MIBG treatment, a NP system that uses MIBG to home to 
neuroblastoma cells and then releases chemotherapy agents in their immediate vicinity may result 
in a better treatment for the disease. This treatment would contain no radioactive properties and 
therefore reduce harsh conditions, which would increase patient compliance and reduce costs. In 
this section, methods to modify PLGA NPs with PEG, followed by MABG, were explored. It was 
found that the attempted reaction schemes, an azide-alkyne Huisgen cycloaddition with MABG, 
was incompatible with PLGA nanoparticles. Additionally, an in vitro model for the testing of 
targeting of neuroblastoma cells was developed and validated. Potential alternative reaction 
schemes are discussed. 
 Methods 
5.2.1 Materials 
Poly(lactic-co-glycolic acid) 5002A (Purasorb®) was purchased from Corbion. Twenty 
kDa 8-arm star PEG-Azide was purchased from Creative PEGWorks. Dulbecco’s Modified Eagle 
Medium (DMEM), Ham’s F12 nutrient mixture, fetal bovine serum (FBS), non-essential amino 
acids (NEAA), penicillin-streptomycin(pen-strep) and Trypsin were purchased from Gibco. 
Desipramine Hydrochloride was purchased from Toronto Research Chemicals. All other reagents 
were purchased from Thermo Fisher or Sigma Aldrich and were of reagent grade or higher. MABG 
was synthesized using the reaction scheme shown in Figure 5.2 courtesy of Dr. Artak Shahnas. 
Briefly, the nitrile group in Figure 5.2A was reduced using Lithium aluminiumhydride as a 
reducing agent. After a workup with K2CO3, the trimethylsilyl (TMS) group was deprotected, 
whereby the 3-Ethynyl-benzylamine (Figure 5.2B) could be obtained in a yield of 70%. The 
obtained amine in Figure 5.2B was then reacted at 60 °C in Tetrahydrofuran with 3,5-
Dimethylpyrazole-1-carboxamidine (Figure 5.2C) and Triethylamine. Upon complete reaction of 
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the starting material, the final product MABG (Figure 5.2D), was obtained in a yield of 85% using 
the ion exchanger Amberlite IRA 400. All compounds were characterized by 1H-NMR, 13C-
NMR, IR, and mass spectroscopy. 
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Figure 5.2 Reaction for the synthesis of MABG. MABG was synthesized by starting with reactant 
(A), which was reduced to product (B). Subsequent amidation resulted in (C), MABG 
5.2.2  Synthesis and Characterization of PLGA and PLGA-Alkyne NPs Using EHD Jetting 
PLGA and PLGA-Alkyne NPs were synthesized using EHD co-jetting using a previously 
established method.189 Briefly, PLGA-5002A was dissolved at a 10% w/v concentration in a 97:3 
mixture of Chloroform and dimethylformamide (DMF), and further spiked with 5% (w/v) of cetyl 
trimethylammonium bromide (CTAB). For PLGA-Alkyne particles, a 75:25 PLGA-5002A: 
PLGA-Alkyne polymer mixture was used. PLGA-Alkyne was synthesized by Dr. Domenic 
Kratzer at KIT. The solution was electro-jetted, and the particles collected using a wet collection 
scrapping method, like that described in previous chapters. Particles were size segregated as 
previously described,189 and subsequently measured for hydrodynamic diameters using dynamic 
light scattering (DLS) or for both size and number concentration with nanoparticle tracking 
analysis (NTA) using a Malvern Nanosight  
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5.2.3 Synthesis and Characterization of PLGA and PLGA-Alkyne NPs Using a Single 
Emulsion Technique 
PLGA and PLGA-Alkyne NPs were synthesized using single emulsion to be able to 
thoroughly investigate the reactions in detail, using a previously established method.266 PLGA-
5002A was dissolved at a concentration of 1% (w/v) in Chloroform, which was subsequently 
diluted 3x in an aqueous solution of 5% (w/v) Polyvinyl Alcohol. The resulting solution was then 
submerged in ice water, and a total energy of 55 W was delivered to the solution using a tip 
sonicator in pulse mode, 1 second on, 5 seconds off. The chloroform was then removed from the 
solution using a rotary evaporator at 38 °C for 1 hour. For PLGA-Alkyne particles, a 75:25 PLGA-
5002A:PLGA-Alkyne polymer mixture was used. Fluorescent NPs were synthesized by doping 
the jetting solution with 1% PLGA-Rhodamine, (w/w%) of total polymer, courtesy of Jason 
Gregory. 
The resulting particles were washed 3 times by centrifuging them for 50 minutes at 4,900 
RCF, and subsequently resuspending the resulting pellet in ultra-pure H2O. The hydrodynamic 
diameters of the resulting particles were measured using DLS, and the number, concentration, and 
particle size with NTA. 
5.2.4 NP Surface Modifications 
PLGA-Alkyne particles were surface modified using two sequential copper catalyzed click 
reactions (Figure 5.3). PLGA-Alkyne particles were suspended in a 0.9 mL volume of ultra-pure 
H2O + 0.1% Tween and the solution sonicated to disperse the particles. 0.1 mL of a 10x mixture 
of Copper(II) Sulfate Pentrahydrate and (+)-Sodium L-ascorbate (prepared by dissolving 13.3 mg 
Copper(II) Sulfate Pentrahydrate and 53.3 mg (+)-Sodium L-ascorbate in 1 ml of ultra-pure H2O 
+ 0.1% Tween) was added. For the first reaction, 90 mg of 8-arm star PEG-Azide was added to 
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the particle solution and tumbled for 24 hours at room temperature. The solution was then chelated 
with EDTA to remove any insoluble copper ions, and subsequently washed 5x using ultra-pure 
H2O + 0.1% Tween. For the second reaction, the same dilutions and Copper(II) Sulfate 
Pentrahydrate/(+)-Sodium L-ascorbate solution was prepared, and 24.98 mg of MABG dissolved 
in 50 μL of dimethyl sulfoxide was added to the reaction mixture. The particles were then chelated 
and washed as previously described. For fluorescent stand in reactions, the same reaction 
conditions were followed, with the replacement of MABG in the second reaction with 1 mg of 
Cy5-Azide. Particles were imaged using a Nikon Eclipse 80i Fluorescent Microscope on a 10X 
objective. 
5.2.5 Particle Characterization Using Scanning Electron Microscopy 
Particle samples were prepared for Scanning Electron Microscope (SEM) by washing them 
10x with Ultra-Pure H2O, followed by sonication to disperse the particles. Multiple serial dilutions 
of particles were prepared, and 10µL of each particle solution was then drop casted onto a silicon 
wafer. The samples were then gold sputter coated and imaged using a Nova 200 Nanolab SEM.  
5.2.6 Cell Culture 
SK-N-BE(2) cells were cultured on plastic cell culture dishes using a 1:1 (v/v) mixture of 
DMEM and Ham’s F12 supplemented with 1% NEAA and 10% FBS. Cells were passaged every 
3-5 days, or when 80% confluent. Cells were only cultured in media supplemented with pen-strep 
during experiments. 
5.2.7 NET Upregulation and Blocking of Neuroblastoma Cell Lines Using Vorinostat and 
Desipramine 
The cytotoxic and protein expression responses of Vorinostat and Desipramine in SK-N-
BE(2) cells were tested. Cytotoxicity was tested using a commercially available XTT assay. NET 
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expression was quantitatively measured using a Wes Simple Western, following manufacturer 
instructions. A rabbit anti-NET antibody was used as the primary antibody (Abcam, ab41559). 
 Results and Discussion 
We first set out to design a NP system that could target neuroblastoma through the use of 
NET. As NET is a channel transporter, and not a surface ligand, it is expected to have low overall 
avidity to an MIBG derivative that is unable to go through the channel. To counteract the expected 
weak interactions, a PLGA system that could take advantage of multivalency was designed. 
Multivalency is an interaction common in biology where a system of ligands and receptors, such 
as MIBG and NET, that have multiple reversible and simultaneous weak interactions. Much like 
Velcro, the combined, numerous interactions can lead to strong binding, and thus multivalency is 
a way to create strong targeting to NP systems with otherwise weak interactions.267 Multivalency 
has been shown, through both in vitro and in silico experiments, to be a way to amplify targeting 
interaction in NPs that otherwise, on their own, are weak.268,269 This binding affinity improvement 
can both increase the residence time of NPs in tumors, which is key to providing therapeutic 
effects, and counteract the decrease of affinity observed when ligands are bound to PEG linkers.270 
 
Figure 5.3 Proposed reaction sequence to produce MABG targeted PLGA NPs 
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 PLGA-Alkyne NPs were first synthesized using EHD co-jetting, but after multiple 
attempts, it was found that while the particles behaved as expected after the first click reaction, 
which PEGylates the surface of the particles, there was a very poor yield of particles after the 
second click reaction to attach MABG onto the surface (Figure 5.3). Additionally, multiple 
attempts at conducting in vitro uptake and targeting assays were inconclusive, and we were unable 
to determine whether the particles were unable to target due to the MABG hypothesis not being 
valid, or manufacturing problems with the fully functionalized NPs. 
To investigate the reason behind this loss of particles, a higher yield synthetic route for the 
PLGA NPs, single phase emulsion, was utilized to be able to thoroughly investigate the reactions 
in detail. A systematic search was then conducted to diagnose the low yield. First, fluorescent NPs 
were PEGylated, and subsequently reacted with a Cy5-Alkyne, which was used as a fluorescent 
stand in for MABG. After thorough washing to remove unreacted reagents, the reaction was 
confirmed with fluorescent microscopy (Figure 5.4). 
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Figure 5.4 The ability of PLGA NPs to be surface modified was confirmed using a fluorescent 
MABG analogue. PLGA nanoparticles were reacted with two sequential copper catalyzed click 
reactions, one to PEGylate the particles, and the second to react Cy5-Alkyne, a stand in for MABG, 
with the terminal azides on the particles. (A) Co-localization of Green (Fluorescent PLGA) and 
Red (Cy5-Alkyne) channels imply success of click reactions. (B-D) are bright field, Cy5, and 
fluorescent PLGA channels, respectively. Controls (no Cy5-Alkyne, and no PEG-Azide but yes 
Cy5-Alkyne) showed only green fluorescence, not shown). Scale bar 100 μm. 
The emulsion synthesized PLGA particles were then reacted using the full reaction 
sequence and measured after each reaction using DLS. A small but notable size increase was 
observed after the MABG reaction, potentially implying that the reaction had occurred. (Figure 
5.5). The NPs were also characterized using NTA. The size measurements using NTA agreed with 
the results from DLS. Number concentration was also acquired, and it was found that similar to 
the EHD co-jetted particles, there was a very poor yield from the MABG reaction, with only a 
3.06% yield. 
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Figure 5.5 Nanoparticle hydrodynamic diameter of functionalized PLGA NPs. Particles were 
measured using DLS before and after each functionalization reaction. A notable size increase was 
observed after the second reaction, where MABG is added to the particles. 
Unlike the EHD co-jetted particles, the yield of the emulsion particles was high enough to 
observe particles using SEM. PLGA, PLGA-PEG, PLGA-PEG-MABG, and PLGA-Control were 
imaged using SEM. PLGA-Control particles were particles that were treated under the same 
reaction buffers, and treated like PLGA-PEG-MABG, but without any reagents. PLGA (Figure 
5.6A), PLGA-PEG (Figure 5.6B), and PLGA-Control NPs (Figure 5.6C), showed no 
morphological differences, in contrast to the PLGA-PEG-MABG NPs, which appeared to be 
degraded (Figure 5.6D). We concluded PLGA particle degradation likely resulted from acid-
induced hydrolysis. We predict this may have occurred in response to deprotonation of MABG, or 
an unidentified byproduct of the click chemistry reaction. 
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Figure 5.6 SEM of modified PLGA particles. (A) PLGA, (B)PLGA-PEG, (C)PLGA-Control, and 
(D)PLGA-PEG-MABG particles were imaged using SEM. It was found that MABG caused 
degradation of the PLGA NPs during the conjugation reaction, possibly due to acidic degradation 
induced by the presence of MABG. 
During the three years that this project lasted, a biological system for the testing of specific 
targeting by MIBG analogues was developed. Using SK-N-BE(2) cells, the dose response of 
Vorinostat, a NET upregulator, and Desipramine, an NET antagonist, was quantified. It was found 
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that SK-N-BE(2) cells showed a dose dependent upregulation of NET when treated with 
Vorinostat, with cells treated with 2.5 μM of Vorinostat expressing 43% more active NET, as 
measured with a quantitative western blot (n=1), without significant cell death (n=3). Desipramine 
was found, as expected, to not affect NET expression, and concentrations that were previously 
used to block NET by Dr. Asish Misra in our lab and in the literature, were not found to affect cell 
viability (Figure 5.7). 
 
Figure 5.7 NET upregulator Vorinostat increases NET expression in SK-N-BE(2) cells, and NET 
antagonist Desipramine has no cytotoxic effects at relevant doses. (A) NET expression was 
measured using a quantitative Western Blot (n=1), and (B) toxicity using an XTT assay (n=3). 
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 Conclusions 
Here, a method for how to use MABG to target PLGA nanoparticles is thoroughly 
investigated. It was found that while it is possible to conduct copper-catalyzed click reactions with 
nanoscale PLGA NPs, MABG induces a degradation reaction on the PLGA NPs and is 
fundamentally incompatible with the particles as a targeting modality, under the investigated 
conditions. Additionally, a method to upregulate NET expression without significant cytotoxicity 
was characterized. New methods developed in the intervening years since this work was 
conducted, such as the surface modification of synthetic protein nanoparticles with azides, make 
it so that it may be possible to study how MABG can be used as a targeting moiety for the treatment 
of neuroblastoma. While the findings of this study were disappointing, they were informative, and 
lay the groundwork to study the use of MABG to target blastomas.
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Chapter 6 
Conclusions and Future Directions 
 In this thesis, various methods for the fabrication of Synthetic Protein Nanoparticles 
(SPNPs) using Electrohydrodynamic (EHD) co-jetting were developed, an investigation of how 
different synthetic parameters affect biological responses was conducted, and anisotropic SPNPs 
were fully characterized. Additionally, a method for loading active enzymes into SPNPs was 
developed and characterized, and their therapeutic and technological potentials explored. 
Furthermore, a method for characterizing single compartment and two-compartment SPNPs using 
electrokinetic microfluidics was demonstrated. Last, exploratory work was shown on how a small 
molecule might be conjugated onto the surface of a nanoparticle for cancer therapeutics. SPNPs 
are a novel technology, and thus there is plethora of available research routes available for further 
exploration and development. 
 Toward in silico Guided Nanoparticle in vitro Experiments 
 In Chapter 2, SPNPs made from a variety of proteins and with different macromers were 
tested for how certain parameters – the proteins and macromers used – would affect how the 
particles would behave in a biological setting, specifically their uptake and degradation behavior. 
In the field of nanoparticle-based drug delivery, these studies are usually conducted using many 
assumptions that treat nanoparticles as if they were small molecules. For example, in the studies 
we conducted, we selected a concentration of particles to incubate cells with and used this same 
concentration for all the studied SPNPs. This assumes that all nanoparticles will physically behave 
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the same, regardless of nanoparticle composition. While this is a perfectly acceptable practice 
when a small molecule (e.g. Vorinostat) is being examined, it may not make sense for 
nanoparticles. A small molecule will quickly diffuse to a steady concentration in surrounding 
media. As it is consumed by the cell, the concentration in the media above the cell will quickly 
equilibrate and be mostly homogeneous at the relevant time scales, following a steady-state 
kinetics approximation. On the other hand, nanoparticles are more complex (e.g. have size 
distributions, interact with each other as well with the surrounding environment, etc.), and are 
influenced by not just diffusion, but also a host of other interactions and physical forces, such as 
aggregation and sedimentation. This leads to particles demonstrating variable measured uptakes 
that may not be based on affinities of the particles to the cells, but on variations in particle settling 
and aggregation.271–273  
 The targeting v. aggregation conundrum has been of particular concern in the field of 
nanotoxicology, where there are broad efforts to create in silico tools to help screen the millions 
of new nanoforms that are being created in industry for environmental and health hazards, both 
short term effects such as toxicity, or effects that could result from long term exposure such as 
genetic mutations. The consensus in the field is that it would be unethical and financially untenable 
to test all the materials being created in the most relevant models (i.e. in vivo murine models). To 
address this, the initial approach was to conduct in vitro testing to screen materials to identify 
potential toxic/hazardous materials for further in vivo testing.272,274–276 This approach has 
problems, particularly the potential of erroneous or misleading results coming not from the toxic 
potential of the particles, but due to the diffusion/sedimentation concerns described previously. As 
a result, models have been developed that seek to predict how particles behave in vitro. The 
foremost current example is the Distorted Grid (DG) model, where particle qualities, like density, 
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effective density, size distribution, alongside characteristics of the surrounding media, like 
viscosity and temperature, are used to model how quickly particles will deposit at the bottom of a 
modeled well of cells.277 These models have gained wide acceptance in the field of nanotoxicology 
but have gained little traction in nanomedicine. With the field beginning to adopt more high 
throughput techniques for drug delivery and toxicity,278,279 similar to the ones that are used in 
nanotoxicology, and the synthetic flexibility of our SPNPs showing their potential as candidates 
in high throughput screening for optimal nanoformulations, implementing models such as the DG 
model into work flows can serve as a tool for quality control and “sanity” checks, preventing the 
in vivo testing of improperly targeted materials. By thoroughly characterizing the particles, and 
subsequently modeling to reflect experimental conditions,280 much insight could be gained about 
particle behavior, whether differences observed are due to true targeting effects or are just an 
artifact from the particle formulation (i.e. identify false positives/negatives). 
 As an example, a meta-analysis was conducted of uptake results from unrelated, 
unpublished uptake studies conducted by Nahal Habibi in order to have a real-world data set to 
compare the DG model against (personal communication, experimental details omitted by 
request).281 Note that none of these particles should specifically target the cells used, theoretically. 
The same particles were then characterized for a variety of parameters, following established 
nanotoxicological protocols,282 and then the deposited fraction was calculated in the same 
experimental conditions with the DG model, using a custom built MATLAB based macro, which 
is available upon request (Figure 6.1).  
 Comparing the results between the experiment and the model provide several new insights. 
For instance, this modeling system can explain discrepancy between experiment and theory. Take 
the uptake results for 200 nm HSA and hTf particles for example. The particles had different 
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uptake levels measured, implying some degree of targeting or increased affinity between the 
particles and the cells. On their own, these results are anomalous, as no targeting would be 
expected in the cells used for these proteins types, but the DG model, based solely on the measured 
material properties of the SPNPs, was able to predict the measured uptake differences. Upon 
further inspection, it was found that the model recognized small differences in the size distributions 
of the particles and was able to quantify the impact of these differences on relative sedimentation, 
and thus measured uptake, rates. 
 
Figure 6.1 In silico models can be used as sanity checks and troubleshooting tools for in vitro NP 
uptake experiments. Various NP and SPNP formulations were given to cells, and the results 
compared to deposited fractions as calculated by the DG model. 
 While these models have potential in being used in screening workflows to rule out false 
negatives or positives, they also have weaknesses that could be improved upon. Take for example 
the contrast between the real uptake and the predicted deposition of amine-modified Polystyrene 
HS
A, 
20
0n
m
Tra
ns
fer
rin
, 2
00
nm
PL
GA
, 2
00
nm
PM
MA
, 2
00
nm
PS
, 2
00
nm
HS
A, 
50
0n
m
Tra
ns
fer
rin
, 5
00
nm
PL
GA
, 5
00
nm
PM
MA
, 5
00
nm
PS
, 5
00
nm
0
50
100
C
om
pu
te
d 
Fr
ac
tio
n 
De
po
si
te
d/
C
el
ls
 C
on
ta
in
in
g 
Pa
rti
cl
es
 (%
)
Experimentally measured uptake (%)
In silico calculated fraction deposited (%)
107 
(PS) particles, where the model predicted very low uptake  rates, while the actual experiment 
resulted in high uptake rates for both sizes of PS NPs. This was due to the amines in the particles 
being positively charged, a parameter that the model does not consider,277 leading to charge 
induced uptake by the cells, whose surface charge is negative. The results presented here provide 
an initial workflow that could be expanded, improved, and integrated into high throughput 
screening of various nanocarriers. These type of in silico based checks could improve the accuracy 
of results, reduce experimental error, and overall improve the translatability of in vitro results into 
in vivo models by ensuring that particles are truly giving potentially positive results because of 
their engineered qualities, and not physics based anomalies due to experimental conditions. 
 Towards Shape Control of SPNPs 
 In Chapter 2, SPNPs were found to be quite flexible in their components, and the 
compositions were shown to have significant effects on the biological behaviors of the particles. 
Another factor in particle behavior has been found to be the particle shape.283,284 Preliminary work 
was conducted to see how particle shape could be modified prior to the macromer 
polycondensation reaction in SPNPs. 
 HSA SPNPs were synthesized, using the NHS-PEG macromers described in Chapter 2, 
and then a sample was either immediately placed in a 37 °C incubator for 1 week (Figure 6.2A), 
or placed in a 37 °C high humidity incubator for 6 hours prior to the 1 week incubation (Figure 
6.2B). As can be seen, the particles that were treated as normal maintained their usual geometry, 
but the particles that were incubated at high humidity first were morphed into “pancake” 
architectures. These pancake shapes are normally seen with EHD jetting when the jetting 
parameters are specifically selected to have low volatility, and thus the particles are not fully solid 
prior to landing on the collection surface and “melt”, forming the “pancakes”. By treating the 
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particles after jetting, the humidity in the environment partially hydrates the particles, and creates 
the same effect. The key difference between the two methods is that changing the jetting conditions 
so that the particles result in “pancakes” normally changes not just the particle geometry, but also 
other characteristics, namely the size of the particles. By using humidity to modify the particles, 
the SPNPs have different shapes but retain similar sizes.  
 
Figure 6.2 SPNPs can be shape shifted after jetting. HSA SPNPs were either (A) treated as 
described in Chapter 2 as a control, or (B) incubated in a high humidity incubator for 6 hours, 
changing their shape to a “pancake-like” geometry. 
 Another key factor in NP delivery is what happens to the particles once they are inside 
cells. NPs are taken up by cells through a variety of different mechanisms, but they almost always 
end up being localized in endosomes which have high levels of enzymes and an acidic environment 
which can reduce therapeutic effect, be it through the breakdown of small molecule therapeutics, 
or denaturation of enzyme therapies such as those used in Chapter 3. A popular strategy of 
particles’ escaping endosomes is through pH triggered swelling.285–287 Thus, preliminary 
experiments were conducted that attempted to control pH dependent swelling in SPNPs. It was 
found that the swelling could be controlled by modulating the material composition of the particles. 
For example, when bicompartmental particles were made with HSA loaded with branched 25 kDa 
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Polyethyleneimine (PEI) in one compartment, and hTf in the other, it was found that particles 
showed little pH dependent swelling (Figure 6.3A). This contrasts to SPNPs made from hTf, that 
when incubated for 24 hours at a pH 4.5, increased in size from 120 nm to 300 nm (Figure 6.3B).  
 
Figure 6.3 SPNPs display material dependent stimuli responsive swelling. SPNPs made in either 
a (A) bicompartmental configuration with HSA PEI in one compartment and hTf in the other, or 
(B) wholly made from hTf, showed different swelling behaviors when place in a pH 4.5 media for 
24 hours. 
 With further development, the two results presented here leave two routes of possible 
research: shape control of particles and controllable stimuli responsive swelling. The first 
technique could be modified (shorter high humidity incubation times, different humidity 
treatments, combination with stretching methods, etc.) to create high aspect ratio SPNPs, leading 
to potentially improved in vivo behavior.288,289 In the second technique, the mechanisms behind 
differential swelling behaviors could be further investigated and used to finely tune swelling 
behavior in the SPNPs, allowing for controlled endosomal escape. 
 Toward Externally Controllable SPNPs 
 As was shown in Chapter 3, SPNPs can be loaded with and maintain the activity of 
enzymes after loading. SPNPs that contain enzymes can be envisioned as the precursors to true 
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medical “nanomachines”, machines that can be controlled and perform functions at the nano- scale. 
The main missing component to using SPNPs as machines  is some kind of external or programable 
control, since currently the SPNPs are only able to be controlled through relatively simple means 
such as substrate or reaction selection, or antibody targeting. 
 
Figure 6.4 Loading SPNPs with magnetic nanoparticles (MNPs) does not significantly change 
their sizes. HRP SPNPs were made with and without MNPs, and their sizes measured using DLS. 
 As an early foray into developing enzymatic SPNPs into nanomachines, external control 
of the particles was implemented by loading enzymatic SPNPs with Horseradish Peroxidase 
(HRP), a popular biotechnology enzyme, and iron oxide Magnetic Nanoparticles (MNP, 0.05% 
w/w of protein), using the Glutaraldehyde (GA) macromers. MNPs were made following a method 
described by Roh and Lahann.290 The inclusion of MNPs the had no significant effect on the size 
of the resulting particles. 
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Figure 6.5 Enzyme and MNP loaded SPNPs can be trapped magnetically in a microfluidic system. 
Various concentrations of SPNPs were loaded into a simple microfluidic device and were trapped 
using an external rare earth magnet. 
 These particles were then placed in a flow through microfluidic system and it was found 
that a strong rare earth magnet was able to capture particles on the inside of the tubing. Trapped 
particles were observed at concentrations down to 1.9 μg/mL through light microscopy (Figure 
6.5). Particles were trapped, washed, and then reacted with a 1-step TMB solution, which would 
change color upon reaction with active HRP. It was found that the particles, after being trapped, 
were still active. The reaction efficiencies for particles trapped in the flow through reactor (i.e. 
substrate was flowed over the trapped pellet and samples from the product measured) and in a 
batch reaction system (i.e. in a microplate assay) were then calculated using the following formula: 
    𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝐸𝐸𝐸𝐸𝐸𝐸𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐸𝐸 =  𝐸𝐸
𝑆𝑆∗𝐸𝐸∗𝑡𝑡
     [1] 
Where P is the amount of product in absorbance units in the flow-through as measured by a plate 
reader, S the mass of substrate placed in the reaction, E the mass of enzyme used, and t the time 
duration of the reaction. It was found that the particles in the flow reactor were 2 orders of 
magnitude more efficient than the same amount of free enzyme in batch reactor conditions, 
6.88x105 Abs·mg-2·s-1 for the “flow” reactor vs 1.07x103 Abs·mg-2·s-1 for the “batch” reactor. 
These results are promise and suggest a future route for research for the development of 
nanomachines. 
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 Toward the Delivery of Biological Therapeutics 
 Gene-therapy holds promise for eradicating some 4,000 described monogenetic diseases, 
such as Angelman Syndrome,291 Cystic Fibrosis,292 Coffin-Lowry Syndrome,293 and Huntington’s 
disease,294 as well as countless acquired diseases. However, traditional gene-therapies rely on 
viral-based delivery platforms which suffer from a host of limitations, such as limited tissue 
specific tropism, variable immunogenicity, toxicity, and limited transgene size.295 There have been 
a variety of attempts to develop non-viral gene delivery platforms using a variety of carrier 
systems, such as liposomes,296 nanogels,297 dendrimers,298 and many others.299 
 Synthetic Protein Nanoparticles (SPNPs) developed by the Lahann lab show significant 
promise as potential gene delivery vectors. Work by Gregory et al. showed that HSA SPNPs are 
able to effectively deliver siRNA in vivo to a glioblastoma bearing mice, a treatment that when 
combined with ionized radiation results in long term survival, a rare achievement in the treatment 
of gliomas.169 As shown in Chapters 2 and 3, the proven potential to load SPNPs with active 
targeting proteins, such as Transferrin, or the possibility to load active gene-modifying enzymes, 
such as Cas9 enzymes,300 adds to the innovative potential of using SPNPs as a gene delivery carrier 
vehicle. 
 To investigate whether SPNPs could be used for the non-viral gene delivery of plasmid 
DNA, we first set out to investigate whether plasmid DNA (pDNA) could be electrojetted. HSA 
and eGFP pDNA was electrojetted, with eGFP at a concentration of 50 ng/mL in the jetting 
solution and crosslinked using NHS-PEG macromers. The particles were imaged using SEM 
(Figure 6.6), and it was found that the pDNA did not affect particle morphology, as compared to 
unloaded SPNPs (see Chapter 2 as a comparison). 
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Figure 6.6 HSA SPNPs loaded with eGFP pDNA. SPNPs can be synthesized with unchanged 
morphology to contain pDNA. 
 The particles, unmodified eGFP pDNA, or electrojetting collectate containing HSA and 
eGFP pDNA was then used to transfect MDA-MB-231 cells in a preliminary study. Lipofectamine 
3000 was used to transfect the non-particle controls. It was found that the SPNPs were unable to 
induce any expression of eGFP in the cells, but it was found that the electrojetted pDNA was still 
able to transfect the cells with eGFP. It was hypothesized that this lack of effectiveness may have 
been due to difficulties with endosomal escape of the particles, as extensive evidence showed that 
HSA SPNPs are readily taken up by cells (see Chapters 2 and 3).  
 To investigate whether endosomal escape was affecting pDNA transfection, a small library 
of bicompartmental SPNPs was synthesized. The particles were designed to have a gene delivery 
compartment, which was loaded with eGFP DNA, and a second endosomal escape compartment, 
loaded with either branched 25 kDa PEI or Pluronic F127 (shortened to F127). It was hypothesized 
that PEI, a cationic polymer shown to cause endosomal escape through the proton sponge effect, 
or F127, a PEG based surfactant which could disrupt phospholipid bilayers and thus also potential 
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cause endosomal escape.126 Particles were made of one of two proteins, HSA, or Human 
Transferrin, hTf, as both proteins have shown promise in various drug delivery applications (see 
Chapter 2). 
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Figure 6.7 Bicompartmental SPNPs can transfect a variety of cancer cells with eGFP pDNA. A 
small library of bicompartmental SPNPs was built, with one compartment loaded with pDNA, and 
the other designed for endosomal escape, loaded with either Polyethyleneimine or Pluronic F127. 
The x-axis denoted the protein that the SPNPs are composed of, and the endosomal escape polymer 
used. 
 A variety of cancer cell lines, HeLa, MIA-PaCa-2 and MDA-MB-231, were then treated 
with the library of particles at a concentration of 10 μg/mL of SPNPs overnight, and the expression 
of eGFP in the cells analyzed using qPCR (Figure 6.7). It was found that SPNPs made from hTf 
and that contained PEI in the endosomal escape compartment were able to significantly transfect 
all cell lines with eGFP expression. It is important to note that it was difficult to quantify gene 
delivery with the particles using eGFP as the delivered gene. eGFP is valuable as its expression 
can be directly observed in cells through fluorescent microscopy, but its fluorescence is not linearly 
related to the expression levels of the protein.  
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To quantify expression, we were forced to use qPCR, which is labor intensive for high-throughput 
applications. 
 In this section, the potential to use SPNPs as a gene delivery device was demonstrated. 
First, the effect of EHD co-jetting on plasmid DNA was quantified, and it was shown that 
electrojetted pDNA is still able to transfect cells with eGFP DNA. Notably, we were able to 
transfect a variety of cancer cell lines with eGFP pDNA by using a bicompartmental SPNPs made 
from Human Transferrin, using PEI as an endosomal escape polymer. Future work should focus 
on the development of a high throughput method to assay gene expression induced by SPNPs, 
perhaps by using a reporter gene like luciferase that is able to give results quickly and 
quantitatively on large-scale microplate assays. This work shows the potential to further develop 
SPNPs into an effective gene delivery device. 
 Future Outlook 
 The work presented in this dissertation provides a foundation for the synthesis, use and 
processing of Synthetic Protein Nanoparticles as a tool for drug delivery. A versatile method for 
their synthesis using a variety of materials was developed. The methods described are flexible and 
allow for multiple routes of research that can be further pursued. For example, particles with 
diverse geometries and anisotropies could be developed to deliver drugs in preprogrammed, 
material dependent, and stimuli responsive fashions. One could also envision the development of 
“nanobiomachines”, SPNPs completely made from bio-derived materials such as proteins and 
carbohydrates, that are able to use enzymes in a preprogrammed manner to self-actuate, self-
locomote, and perform actions, such as catalyze a chemical reaction, or transcribe cells with a 
genes, once at the desired location.  
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 Much development is left to create technologies such as these, namely more sophisticated 
macromers whose chemistries are more controllable, work at smaller time scales, and use more 
bio-derived materials – perhaps engineered proteins with artificial amino acid residues. 
Additionally, release profiles of different drugs must be characterized, both in single and multi-
compartment configurations of SPNPs, to completely characterize their therapeutic potentials. 
These, and many other unforeseeable hurdles must be crossed, but SPNPs made by EHD co-jetting 
hold significant potential to be impactful nanodevices.
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Appendix A 
A Brief Geometric Analysis of Substrate Diffusion in Enzyme Loaded Synthetic Protein 
Nanoparticles 
 Applying 1D diffusion, we find that the following equation can be used to estimate whether 
a chemical reaction in a sphere will be diffusion limited: 
Ø = 𝑞𝑞𝑟𝑟2
𝐷𝐷𝐷𝐷
 
 Where q is the reaction rate of the chemical reaction, r is the radius of the sphere, D is the 
rate of diffusion of the substrate, and C is the bulk concentration of the substrate. Ø is a 
dimensionless number. In this analysis, it is assumed that the substrate concentration is high 
enough for q to be independent of C, and C(r)>>0. In a sphere, if Ø << 6, the diffusion rates are 
high enough to feed the reaction, and thus the reaction is not diffusion limited. This can translate 
over to a nanoparticle loaded with enzymes. In a particle that is diffusion limited, reaction rates 
will seem lower than an equivalent particle system that is not diffusion limited (higher C, smaller 
r). 
 Using this, we can estimate whether the two particle systems investigated are diffusion 
limited. Assuming that proteins have a mass to volume ratio of.301 
𝑉𝑉 = (1.212 ∗ 10−3) ∗ 𝑀𝑀 (𝐷𝐷𝑅𝑅) 
 Alongside knowing the reaction rates of our proteins (2.8x106 molecules/protein for 
Catalase, 641 molecules/protein for Glucose Oxidase), the concentration of substrate in our 
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reaction, and the diffusion rates of the substrates in the nanoparticle (assuming Glucose will diffuse 
similarly to water in our particles,302 and the rate for Hydrogen Peroxide was obtained from 
literature),303 we can calculate Ø for the particles, and for particles that are made of enzymes at 
different loading rates : 
Protein (w/w%) Ø 
Catalase 
5:95 585.7 
10:90 1193.6 
25:75 3164.0 
50:50 7034.8 
GOX 
5:95 0.0099 
10:90 0.0203 
25:75 0.0540 
50:50 0.1202 
 
 This result is intuitive. Catalase, which is the enzyme with the fastest known turnover rate, 
is incredibly diffusion limited, as all substrate that approaches the surface is quickly reacted. To 
achieve a particle that is not diffusion limited with the sizes possible using EHD co-jetting, 
particles would have to be loaded in the range of 0.0001% loading (around 2 enzyme molecules 
per nanoparticle). Glucose Oxidase, on the other hand, has a much slower reaction rate and this 
results in that all the particles are not diffusion limited. Even particles that are completely made of 
enzyme have Ø=0.31. 
 To compare these results to experimental data, it is most useful to look at the retained 
activities of the particles as a function of loaded enzyme(Figure 3.5A). As can be seen, both 
particle types seem to be diffusion limited, as the retained activities decrease as the amount of 
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enzyme in the particles increase. This disagrees with the analysis that predicts that the GOX 
particles should not be diffusion limited and thus the activity should stay constant, regardless of 
the loading. 
 This analysis does not cover the full picture. The substrates likely do not have the diffusion 
rates that are found in literature, as they have never been studied in this specific system. For 
example, it is well known that carbohydrates interact with proteins, HSA in particular, and this 
likely reduces the diffusion constant of glucose within the SPNPs.304–307 Additionally, this analysis 
does not take into account enzyme inactivation, which is most likely occurring in the particles at 
some level. A full analysis of these particles would require measurements of the diffusion constants 
of each substrate within the protein matrices, which is outside the scope if this study. 
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Appendix B 
Useful Protocols for Nanoparticle Surface Modification and Confocal Microscopy 
Surface Modification with Copper Catalyzed Click Chemistry 
 This is a general protocol for the surface modification of Nanoparticles that are 
functionalizes with azide or alkyne groups. It can be modified for specific applications. Brands 
described were the ones used, but may be substituted 
Materials Needed 
• DI H2O + 0.1%Tween 
• Copper(II) Sulfate Pentrahydrate (CuSO4.5H2O) 
• (+)-Sodium L-ascorbate (C6H7NaO6) 
• 0.01M Ethylenediaminetetraacetic acid (EDTA) 
• 15 mL Centrifuge Tubes (Falcon Brand) 
• 2.0 mL Microcentrifuge Tubes (Fisher Brand) 
Procedure 
1. Quantify your particle yield, be it by particle number, mass, or assays such a BCA 
2. Pellet your particles, remove the supernatant, and resuspend the pellet in 900 μL of DI 
H2O + 0.1% Tween. Sonicate for 5 sec at 1 sec on/5 sec off to disperse particles. 
3. Make a 10x solution of Copper(II) Sulfate Pentrahydrate and (+)-Sodium L-ascorbate 
(13.3 mg CuSO4.5H2O + 53.3 mg C6H7NaO6 in 1 mL of DI H2O + 0.1% Tween). Mix 
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until orange. Do not make a stock, place on rotator immediately after solubilizing and 
keep on rotator until used. 
4. Add 100 μL of 10x CuSO4.5H2O/C6H7NaO6 solution to the particle solution. 
5. Add your desired mass of reactant. Aim for 5-10x molar excess to the estimated number 
of corresponding click reaction groups on your particles, be it azide or alkyne 
6. Place on a rotator at room temperature, covered in foil, for 24 hours. 
7. If the solution is clear: Wash with 5x with DI water and 0.1% tween. 
8. If the solution is brown, or the pellet is brown if when you centrifuge down the particles 
for washing:  
a. Centrifuge and remove supernatant. Add 2 ml of EDTA solution and resuspend 
pellet. Leave for 2 hours or until solution is clear (but not more than 3 hr). If after 
3 hr the solution is still brown, centrifuge, remove supernatant, and incubate with 
EDTA again. If you used too much copper, it might take a couple of times of this. 
Make sure to wash 5x with DI/tween after this to remove all the EDTA, as it is 
pretty toxic. 
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Cell Staining to Image Cells for Nanoparticle Uptake 
 This protocol is to stain cells after conducting an uptake experiment. This procedure 
begins after the incubation time of cells with particles is over. The volumes suggested assume 
that the cells were cultured in an 8 well chamber slide with removable wells (Nunc Lab-Tek II 
Chamber Slide System), but the volumes may be adjusted to be higher or lower, as long as the 
volumes used completely cover the bottom of each well. The specific dyes described here will 
stain a nuclei blue (DAPI laser line), and the actin fibers green (FITC laser line). This protocol 
has been used to stain HeLa, REN, and SK-N-BE(2) with good results, and should work with 
most adherent cell lines, but the specific dye concentrations may need to be adjusted to obtain 
optimal images.  
Materials Needed 
Percentage values are all mass based, except for formalin and Alexa-488 Phalloidin, which is 
volume based. 
• Sterile PBS for cell fixation steps 
• Clean PBS, no need for sterility but should be a container specifically used for staining 
• Fixing Solution 
o PBS + 4% formalin, or commercial methanol free fixing agent. 200 μL per 
sample. 
• Permeabilization Solution 
o PBS + 0.1% Triton-X + 1% BSA. 250 μL per sample. 
• Blocking Solution 
o PBS + 1% BSA, 1 mL per sample. 
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• Staining Solution 
o PBS + 2.5% Alexa-488 Phalloidin + 1% BSA. 250 μL per sample. 
• Prolong Diamond + DAPI 
o Allow to come to room temp before use, Around 10 μL per sample. 
• Coverslips for your desired application 
o Be careful, coverslips of the wrong thickness can distort images in confocal 
microscopy. 
o I like corning brand (Corning #2980225) for chamber slides. 
Procedure 
Cell Fixation 
• Remove experimental media, and carefully wash each well with sterile PBS (with same 
volume used in experiment, gently sway slide back and forth 3-4 times for all washes) 
• Remove PBS 
• Add 200 μL 4% formalin/PBS mix, incubate for 10 min 
• Remove formalin 
• Wash at least 2 times w/PBS 
Stop point: Samples can be stored at this point for a week at 4 °C, covered well in foil, 
preferably with lid parafilmed. I try to stain within 2-3 days. 
Alexa-488 Phalloidin Stain 
• Incubate with 200 μL of 0.1%Triton-X+1% BSA in PBS for 3-5 minutes. 
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o Very time sensitive. Try to treat all your wells for the same amount of time to ensure 
even staining. 
• Wash at least 3 times w/ PBS + 1% BSA, leave last wash in the well. The last wash should 
stay in the well for 20-30 minutes. 
o This is your non-specific staining blocking step. The longer you incubate, the 
dimmer your Actin stain will be, but the lower your background. HeLa cells worked 
well with a 20-minute incubation. 
• Remove the PBS wash and place 200 μL of the below solution in each well. 
o PBS + 2.5% Alexa-488 Phalloidin + 1% BSA 
• Incubate in a dark box for 20 minutes. 
• Wash at least 2 times w/PBS 
Fixing with Prolong Diamond + DAPI 
• Remove last wash, remove slide wells, and allow to air dry in the dark (around 20-30 
minutes). 
• Place a drop of Prolong Diamond + DAPI (around 10 μL) on each well, and place coverslip 
on top.  
o Be gentle and careful, try to avoid bubbles.  
o Allowing the Prolong Diamond to fully come to room temp, and letting it sit for 20 
or so minutes so all the bubbles rise will help with this. 
• Allow Prolong Diamond to cure in a dark place for at least 24 hr. 
Tips for a successful stain: 
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• My recommendation is that you stain no more than 2 slides at a time until you are well 
practiced at the procedure.  
• Make your solutions before you start working. 
• You can make stocks of 100X Triton-X and 10X BSA, but keep track of when you make 
the solutions, store at 4 °C, and do not use past 2-3 months, or if you see visible precipitates. 
• Work in the dark to stop photobleaching. My practice is to use a non-direct source of light 
to see by. 
• Key is consistency, patience, gentleness, and consistency. Yes, that was on purpose, getting 
consistent stains is probably the hardest part of all of this. 
• Take your time, except for the points that have specific incubation times. If you rush it, 
you will reduce with the quality of your stain. 
• Make sure to minimize touching the bottom of the well with your pipette. My practice is 
to pick a corner, and always have that be the part you touch when removing volumes. 
• Always switch tips when removing solutions, but you can reuse tips when adding solutions 
if you are sure that no part of the well has been touch by the tip. 
• When adding liquids to wells, “waterfall” them down the walls of the well. Do not directly 
release the volume over the bottom of the well, this can damage/cause cells to detach. 
• Placing coverslip atop the cells with the Prolong Diamond without introducing bubbles is 
tricky. I recommend practicing either with a slide that has nothing in it, or with your 
controls, before working with experimental samples. 
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